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Malaria stills remains one of the leading causes of death in sub-Saharan Africa, with P. falciparum 
being the most virulent strain of Plasmodium. Due to the emergence of drug resistance, new 
antimalarial agents are needed to circumvent this. Similarly, in the treatment of cancer, there is an 
urgent need for the design and development of new antineoplastic agents. This work describes the 
design, synthesis and biological evaluation of chromone-aminoquinoline hybrids as potentially new 
chemotherapeutic agents. A series of chromone-based hybrid molecules were synthesized using 
either reductive amination or amide coupling reactions. The compounds were synthesized in order 
to evaluate their antiplasmodial, antitumour and antimycobacterial activity. Each hybrid was fully 
characterized using NMR, IR and mass spectrometry techniques. Aminoquinolines were attached 
with alkyl or amide linkers at position 3 and an amide linker at position 2 of the chromone ring to 
produce covalently-linked hybrids. Series 1 contained the alkyl-linked hybrids at position 3 of the 
chromone ring, these compounds generally exhibited potent antiplasmodial activity with SN24 (D10: 
IC50 = 30.7 nM) displaying the greatest potency. Series 2 contained the amide-linked hybrids at 
position 3 of the chromone ring. The compounds in this series also displayed potent antiplasmodial 
activity, the most potent compounds being SN44 (NF54: IC50 = 38.1 nM), SN48 (D10: IC50 = 20.9 nM), 
SN54 (D10: IC50 = 46.8 nM; NF54: IC50 = 57.5 nM) and SN57 (D10: IC50 = 39.7 nM; NF54: IC50  
= 63.3 nM). Additionally, compounds with the aminoquinoline ring at position 2 of the chromone 
ring displayed enhanced potency as compared to the analogues with attachments at position 3, 
especially in the K1 strain of P. falciparum. In this group SN74 (IC50 = 82.9 nM), SN77 (IC50 = 37.6 nM) 
and SN78 (IC50 = 80.9 nM) were the most potent compounds against the K1 strain of P. falciparum. 
All hybrids were evaluated for their antitumour activity against the oesophageal cancer WHCO1 cell 
line, and displayed moderate activity, with SN78 (IC50 = 1.78 μM) being the most active. Poor 
antimycobacterial activity was observed in these chromone-based hybrids. Physicochemical 
properties were determined, such as turbidimetric aqueous solubility at pH 7.4 experimentally as 
well as CLogP, CLogD and Caco-2 were predicted. The hybrids displayed low to moderate solubility  
(2 – 47 μg/mL). The effect of the aryl substituents on the chromone motif was also investigated in 
terms of solubility and pharmacological activity. Aryl substituents were attached at various positions 
of the chromone ring via the Suzuki cross-coupling reaction to produce biaryl chromone ethyl ester 
analogues. These biaryl chromone esters displayed low solubility (1 – 7 μg/mL), while compounds 
with aryl substituents at positions 5 and 8 of the chromone ring displayed high solubility (60 μg/mL), 
due to the possible disruption of planarity of the molecule. These chromone-ethyl esters exhibited 
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Chapter One – Introduction and Background 
1.1 Malaria – Background/Introduction 
Malaria continues to be one of the greatest threats to mankind, as it is one of the most dangerous 
infectious diseases.1 Malaria is endemic in 106 countries as of 2010, and is mainly found in tropical 
areas such as sub-Saharan Africa, Southeast Asia and Central and South America.2 With increasing 
indication of climate change, global warming in particular, there is great concern over the possibility 
of the spread of malaria to regions that are currently declared malaria-free.3 Over 216 million 
malaria-related clinical cases are reported yearly. The World Health Organization (WHO) estimates 
that malaria kills over 655 000 people annually; most deaths are of pregnant women and children 
under the age of five, with 91 % of these cases being in sub-Saharan Africa.4 The African economy is 
also affected as a consequence as malaria endemic countries tend to have lower rates of economic 
growth per capita when compared to non-endemic countries.5 Travellers visiting malaria endemic 
countries are also at risk.6 Malaria is said to be a third world country disease and as such, one of the 
biggest challenges in the management of malaria is to provide cheap and affordable medication.7  
1.1.1 Life Cycle of the Malaria Parasite  
Malaria is caused by a unicellular protozoan parasite of the genus Plasmodium. There are four 
species of Plasmodium that infect humans: P. falciparum, P. malariae, P. ovale and P. vivax.  
P. falciparum is the most virulent species in Africa, Asia and South America.8 P. knowlesi, which was 
known as a primate form of Plasmodium, has also been reported to cause human infections.9 The 
human malaria parasite has a complex life cycle (Fig. 1.1) that requires a human host for asexual 
reproduction and a vector host for sexual reproduction. When an infected female Anopheles 
mosquito bites a human, wormlike single-celled parasites called sporozoites are ejected from the 
salivary glands of the mosquito into the host’s bloodstream. The sporozoites begin the exo-
erythrocytic cycle by migrating to the liver, where they invade hepatocytes and develop into tissue 
schizonts. After maturation of the schizonts the hepatocytes rupture, releasing merozoites into the 
blood stream. Once in the blood, the merozoites invade red blood cells, commencing the 
erythrocytic cycle. During this cycle, the parasites develop into metabolically-active trophozoites by 
metabolizing oxygen-carrying haemoglobin (Hb) and proteolysis of haemoglobin to amino acids. The 
erythrocytic cycle ends when the red blood cell bursts, releasing merozoites and harmful toxins into 
the bloodstream. This rupture (approximately 48 hours for P. falciparum, P. ovale and P. vivax and 
72 hours for P. malariae) coincides with the clinical symptoms of malaria, such as high fever, chills, 
convulsions and anaemia. In the case of severe malaria, symptoms like metabolic acidosis and multi-
organ failure are experienced; this may lead to coma or death. The merozoites released are now 
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differentiate into gametocytes, which are taken up when the infected human host is bitten again by 
a female Anopheles mosquito. These develop into male and female gametes in the stomach of the 
mosquito. Upon fertilization, an ookinete is formed, which invades the mosquito gut wall and forms 
an oocyst. The oocysts mature and rupture to release sporozoites which travel up to the salivary 
glands of the mosquito to recommence the cycle.10, 11  
 
 
Fig. 1.1: Life cycle of the malaria parasite10 
 
1.1.2 Antimalarial Therapy and Classification of Antimalarial Drugs 
The complexity of the multiple stages in the malaria lifecycle requires the use of multiple strategies 
for its control. One way of achieving this is vector control; which is primarily targeted at reducing the 
number of infectious mosquitoes. The WHO has distributed bed nets and screens to malaria affected 
areas and have begun spraying insecticides, such as bendiocarb, indoors.12, 13 This strategy is 
hampered by the development of resistance to the insecticide by the mosquito.13 Other strategies 
include malarial chemotherapy and prophylaxis. The life cycle of the malaria parasite is the target for 
current antimalarials.14 The exo-erythrocytic cycle is the ideal target for the development of 
antimalarials, as this is where the parasite first starts to replicate. However, this is prior to the 
development of typical malaria-like symptoms and can be very challenging to treat as people are 
unaware that they are infected.15 Due to difficulties in studying the liver stage in more detail, most 
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When designing a drug for P. falciparum, the following are necessary criteria: 
 Highly efficacious against resistant strains of P. falciparum 
 Short duration of the medication regimen to ensure patient compliance  
 Formulation of an orally-active dosage 
 Safety in young children, pregnant women and immuno-compromised individuals 
 Stable, with a long shelf-life under tropical conditions 
 Ability to be used in combination therapy 
 Cheap and affordable16, 17 
The majority of current antimalarials were not developed through rational design but rather through 
discovery of the antimalarial activities of natural products, such as quinine and artemisinin or 
compounds derived from natural products such as artesunate.16 Advances in technology have 
effectuated the completion of the P. falciparum genome sequence. This has allowed for a better 
understanding of the parasite’s biochemistry, as well as its molecular and cellular biology.18 The 
genome project has revealed potentially new parasite-specific targets which are essential for 
combating the emergence of resistance. Currently available antimalarials can be grouped into two 
categories: drugs that act on specific stages in the parasite’s life cycle and drugs based on their 
modes of action.19, 20  
1.1.2.1 Drugs that act on Specific Stages in the Parasite’s Life Cycle 
Antimalarial therapy can be classified based on which stage in the life cycle it inhibits. Blood 
schizonticides are active against the asexual erythrocytic cycle, whereas tissue schizonticides target 
the liver stage and prevent relapse of malaria. The use of gametocytocidal drugs kills non-pathogenic 
gametocytes and blocks the transmission of gametocytes from the human host to the vector host. 
Sporontocides, on the other hand, inhibit the development of oocysts and sporozoites in the 
mosquito, preventing parasite transmission.21  
1.1.2.2 Drugs Based on Mode of Action 
This group consists of drugs based on their modes of action. The majority of antimalarial drugs in 
clinical use fall under one of the four categories: 
 Inhibitors of haemozoin formation 
 Inhibitors of nucleic acid synthesis  
 Inhibitors of cysteine protease, and 
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Inhibitors of Haemozoin Formation 
The malaria parasite requires a large amount of nutrients for its development, but lacks the capacity 
to synthesize its own amino acids de novo or to scavenge them.23 Therefore, the malaria parasite 
takes up the cytoplasm of the erythrocyte, which contains haemoglobin to carry oxygen to the bodily 
tissues. The encapsulation of the cytoplasmic haemoglobin into vesicles by the parasite is known as 
endocytosis.24 These vesicles deliver the ingested haemoglobin to the food vacuole (FV). The food 
vacuole is a single-membrane organelle with a pH of 4.8 – 5.2, which is host to a variety of 
biochemical processes.25 In P. falciparum infections, over 70 % of haemoglobin in red blood cells is 
degraded by the parasite and used as a major source of nutrients.26 Haemoglobin is digested in the 
food vacuole  by aspartic proteases such as plasmepsin I, II and IV, histo-aspartic proteases, cysteine 
proteases falcipain 2 and 3 and falcilysin, a zinc metalloprotease.26–29 Haemoglobin  proteolysis 
produces amino acids and free haeme (ferriprotoporphyrin-IX or Fe(II)PPIX) in the cytosol of the 
parasite.30 The iron centre of the free haeme is oxidized from Fe(II) to Fe(III), forming haematin 
(aqua/hydroxoferriprotoporphyrin IX or H2O/HO-Fe(III)PPIX), also called the malaria pigment.
31 A 
build-up of haematin is toxic to the parasite, as this leads to the generation of reactive oxygen 
species. These highly reactive intermediates disrupt cell structure by reacting with proteins and 
lipids.32 The parasite has an internal mechanism to overcome this problem, by converting haematin 
to haemozoin, an insoluble inert crystal.33, 25 The crystal structure of haemozoin was elucidated in 
1991 by Slater and co-workers and later confirmed by Pagola and co-workers.34, 35 The current model 
reveals that haemozoin is a cyclic dimer of haematin, with a bond between the Fe of one haeme to 
the carboxylate group on another haeme (Fig. 1.2).  
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Therefore, drugs that belong to this class interrupt haemozoin formation, as these drugs are 
designed based on β-haematin, a synthetic cyclic dimer of ferriprotoporphyrin IX, which is 
structurally, spectroscopically and crystallographically identical to haemozoin.37 The  
4-aminoquinolines (chloroquine and amodiaquine), quinoline methanols (quinine and quinidine) and 
aryl alcohols (mefloquine and halofantrine) form part of this group (Fig. 1.3).38 These drugs are 
believed to work by forming complexes with haeme through π-π stacking of their planar aromatic 
groups, hence blocking the conversion of haeme to haemozoin.39  
Chloroquine (CQ) is a blood schizonticide which acts on the trophozoite stage in the life cycle and 
had been the drug of choice in the treatment of malaria for decades.40 However, the use of 
chloroquine has been hampered by widespread drug resistance in the parasite.40 Chloroquine is 
thought to work in the acidic food vacuole (FV) of the malaria parasite. Chloroquine exists as a 
neutral species and crosses the vacuolar membrane against a pH-dependent gradient. This is 
accomplished by the lipophilic nature of the aminoquinoline core, once in the acidic food vacuole 
the nitrogen atoms become protonated and the resulting species is unable to cross the membrane 
again, leading to their accumulation within the food vacuole. This process is known as pH-trapping, 
where a free base diffuses across the membrane and is trapped in the food vacuole as it becomes 
protonated. Once inside the food vacuole, chloroquine forms a complex with haematin via π-π 
stacking with the porphyrin ring system on haematin and the quinoline nucleus.41 This association 
further enhances drug accumulation within the food vacuole.42, 43 The conversion of haematin to 
haemozoin is inhibited, resulting in an increase in toxic haematin and chloroquine-haematin 
adducts, which in turn leads to the inhibition of enzyme activity, resulting in parasite death and 
erythrocyte lysis.44, 45  
Due to the emergence of drug resistance, the WHO facilitated the design and synthesis of new 
antimalarials such as mefloquine and halofantrine.11 Mefloquine is a fluorinated quinoline alcohol, 
which has good antimalarial activity against chloroquine-resistant (CQR) strains of P. falciparum.46 It 
has been used as a prophylactic due to its long half-life of 14 – 21 days. However, it is believed that 
this may have contributed to the rapid development of resistance against it.17 Halofantrine (Fig. 1.3), 
also an aryl alcohol, is metabolized into its active agent, desbutylhalofantrine.47 Halofantrine was 
reported to have excellent activity against CQR strains of P. falciparum, however, due to poor 


















Fig. 1.3: Examples of inhibitors of haemozoin formation 
 
Inhibitors of Nucleic Acid Synthesis 
This class consists of the dihydrofolate reductase inhibitors such as pyrimethamine and proguanil. 
The action of dihydrofolate reductase can be blocked by antifolates, which cause a decrease in 
tetrahydrofolate, an essential molecule in DNA synthesis (Fig. 1.4).49, 50 Sulfadoxine, a 
dihydropteroate synthase inhibitor, also belongs to this class; it acts by mimicking para-
aminobenzoic acid (PABA) and interacts with the active site through competitive inhibition (Fig. 1.4). 
This inhibition causes a decrease in the synthesis of essential amino acids such as serine and 
methionine.51  
 
Fig. 1.4: Examples of inhibitors of nucleic acid synthesis: pyrimethamine, proguanil and sulfadoxine 
 
Inhibitors of Cysteine Proteases  
Cysteine proteases play an important role in the erythrocytic cycle as they are involved in the 
haemoglobin  degradation process.52 Recent studies have shown that falcipain cysteine proteases 
can be inhibited, which results in inhibition of haemoglobin hydrolysis.53 Cysteine protease inhibitors 
block the rupture of erythrocytes at the end of the erythrocytic cycle. Peptidyl fluoromethyl ketones 
and vinyl sulfones have displayed antimalarial activity in the nanomolar range both in vitro and in 
vivo.53–55 Extensive studies on non-peptidyl cysteine proteases inhibitors such as phenothiazines, acyl 
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Activators of Oxidative Stress  
Compounds that generate oxidative stress can trigger apoptosis or programmed cell death.58 
Reactive oxygen species (ROS) are produced as by-products of oxygen metabolism, and also produce 
oxygen radicals that are able to disrupt cell structure by interfering with the lipid bilayer. 
Plasmodium parasites have detoxification mechanisms to deal with these radicals. However, drugs 
that are able to increase ROS may overcome the cell’s internal defence mechanism, resulting in cell 
damage and eventually lysis.59 This class contains the artemisinins and the 8-aminoquinolines.60 
Artemisinin and its derivatives dihydroartemisinin, artemether, arteether, artesunate and artelinic 
acid (Fig. 1.5), are believed to generate oxidative stress via the endoperoxide bridge. Primaquine, an 
8-aminoquinoline, (Fig. 1.5) is the only approved drug against the hepatic stages of malaria parasites; 
it is extensively used in the treatment of P. vivax (the species that causes recurrent malaria).  
 
Fig. 1.5: Examples of compounds that generate oxidative stress in the malaria parasite 
 
1.1.3 Resistance 
The widespread use of chloroquine worldwide and especially in Africa resulted in the emergence of 
chloroquine-resistant strains of P. falciparum and P. vivax. Drug resistance in malaria has been 
defined as ‘the ability of a parasite strain to survive and/or to multiply despite the administration 
and absorption of a drug given in doses equal to or higher than those usually recommended but 
within the limits of tolerance of the subject’.61 However, this definition has now been modified to 
specify that the drug ‘must gain access to the parasite or the infected red blood cell for the duration 
of the time necessary for its normal action’.62, 63 Resistance generally occurs through spontaneous 
mutations; for some drugs, a single mutation is enough to lead to resistance, while in other drugs 
multiple mutations are needed.64 In sub-Saharan Africa, the morbidity of the disease, in addition to 
the development of resistance, is further amplified by the prevalence of malnutrition among 
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approaches in medicinal chemistry and drug discovery to develop new antimalarials, including 
combination therapy, the development of natural products, drug rotation, the redesign and 
repositioning of existing drugs and the use of resistance reversal agents.65–67 
Combination Therapy 
The WHO defines combination therapy in malaria as ‘the simultaneous use of two or more blood 
schizontocidal drugs with independent modes of action and different biochemical targets’ and has 
mandated the use of combination therapy as the most effective way to circumvent resistance, as the 
combination is often more effective; in the rare event that the parasite is resistant to one of the 
medicines, the parasite will be killed by the other component of the therapy.9, 65 The use of 
combination therapy is validated as reports suggest that if resistance arises from mutations in the 
target protein, then administrating drugs with different modes of action may reduce the chances of 
the parasite developing resistance.68 Artemisinin-based combination therapy (ACT) is recommended 
by the WHO as the first-line treatment option for malaria, where one of the components is 
artemisinin or one of its derivatives (artesunate, artemether or dihydroartemisinin). Artemisinins 
produce quick clearance of parasitaemia but have a short half-life. They are thus given in 
combination with slowly eliminated antimalarials. Currently, there are five ACT combinations that 




 Artesunate-sulfadoxine/pyrimethamine, and 
 Dihydroartemisinin-piperaquine9, 8 
Artemisinins are most effective during the erythrocytic cycle and are also known to reduce the 
number of gametocytes in the blood. ACTs have been used to successfully treat CQR strains of  
P. falciparum and multidrug-resistant malaria.69 The use of ACTs in South Africa has brought about a 
decline in the amount of malaria transmissions and no clinical resistance has been reported for the 
ACT regimen.69 However, reports from Western Cambodia suggest that resistance is currently 
developing.70 If the first-line treatment plan has failed, artesunate or quinine is given as a 
combination with tetracycline, doxycyline or clindamycin. The use of chloroquine in combination 
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1.2 Cancer – Background/Introduction 
Cancer is one of the most common diseases in both developing and developed countries around the 
world.71 According to the WHO, at least one in every three people will be affected by some kind of 
cancer. In South Africa, according to the Cancer Association of South Africa (CANSA), the most 
prevalent cancer in males is prostate cancer and in females, breast cancer.72 Cancer is caused when 
normal cells lose their regulatory mechanisms that control replication and differentiation. In normal 
cells, the rate at which cells grow is equal to the rate at which they die, whereas in cancerous cells 
this balance is disrupted.58 This results in rapid accumulation of cells or a neoplasm, more commonly 
known as a tumour or cancer. If the rapid growth of cells is localized to a specific area, the tumour is 
called benign and is easier to treat. However, if cancer cells invade other parts of the body and 
develop into secondary tumours, they are termed malignant. This is a more serious type of cancer, 
which is life-threatening and more difficult to treat.73  
There are over 200 different cancers that affect humans; therefore treatment that controls one form 
of cancer may not be effective for another. Cancer can be caused by various factors; these include 
lifestyle factors such as poor diet, smoking and alcohol abuse as well as environmental factors such 
as exposure to carcinogenic chemicals and genetic factors. (Fig. 1.6).73 
 




Proto-oncogenes control cell division and differentiation. If mutations occur, this disrupts normal cell 
function, allowing cells to become cancerous. The proto-oncogene is now called an oncogene, a 
gene that is able to cause cancer.75 If DNA is damaged in normal cells, cells have repair mechanisms 
that can detect damage and block DNA replication. This allows the DNA repair mechanisms to work 
and repair the damage. If the DNA cannot be repaired, the cell commits suicide, a process known as 
programmed cell death or apoptosis.24 Tumour-suppression genes code for the proteins that are 
involved in the cell’s repair mechanisms. If there are defects in these genes, the chances of cells 
becoming cancerous increases; these defects are also passed from generation to generation. Many 
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These hallmarks are: 
 Evading growth suppressors 
 Activating invasion and metastasis 
 Enabling replicative immortality 
 Inducing angiogenesis 
 Resisting apoptosis 
 Sustaining proliferation signaling76 
 
Cell Cycle 
Most anticancer drugs inhibit a particular stage in the cell cycle. The cell cycle in eukaryotes is 
divided into two phases: the interphase and the mitosis phase (Fig. 1.7). During the interphase the 
cell grows, accumulates nutrients necessary for mitosis and begins DNA replication. The interphase 
consists of three phases: the G1 phase or the growth phase, followed by the S phase, the DNA 
synthesis phase, then followed by the G2 phase, which involves the biosynthesis of microtubules; 
cells remain in the G2 phase until they enter the mitosis phase. The mitosis phase, or the M phase, is 
the phase that separates the chromosomes in the nucleus into two identical sets in two separate 
nuclei; this is immediately followed by cytokinesis, the final stage in the cycle in which cytoplasm is 
divided and two daughter cells are produced, which are genetically identical to each other and the 
parent cell. There are mechanisms within the cycle to detect errors in the replication process that 
bring about programmed cell death. However, if these fail to recognise errors or mutations, 
cancerous cells may develop.24, 73 
 




Traditionally, there are three approaches in cancer treatment: surgery, radiotherapy and 
chemotherapy. However, due to advances in technology and a better understanding of the 
molecular biology of cancerous cell, hormone and photodynamic therapies are also used. Only the 
use of chemotherapy will be discussed here; for the other forms of treatment, please refer to the 
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1.2.1 Chemotherapy  
Chemotherapy is the use of drugs to weaken and destroy cancer cells. This therapy usually affects 
the whole body. Chemotherapy is normally administered alongside surgery and radiotherapy. 
Anticancer agents work by accumulating in cancerous cells rather than normal cells. The difficulty 
with most chemotherapeutic agents is that they are unable to differentiate between normal cells 
and cancerous cells. These agents target cancer cells, as these cells are fast-growing and need to 
gather nutrients and synthetic building blocks.73 In the body, there are other fast growing cells like 
bone marrow cells and hair cells which are also affected by anticancer agents. This results in bone 
marrow toxicity and rapid hair loss. Damage to bone marrow cells results in weakening of the 
immune system, which increases the chances of secondary infections in cancer patients.73 
Anticancer drugs exhibit their action by inhibiting cell differentiation, by interacting either directly or 
indirectly with DNA. Drugs that block DNA function indirectly act by inhibiting enzymes that are 
involved in DNA synthesis. Still, cancer therapy is becoming more sophisticated as more information 
becomes available on the cellular chemistry of cancer cells.  
1.2.1.1 Anticancer Drugs that act directly on DNA  
This class of drugs interact directly with the nucleic acids on the backbone of DNA. Disruption of DNA 
function can lead to cell death. These include the intercalating agents, non-intercalating agents and 
the alkylating agents. 
 
Intercalating Anticancer Agents 
These drugs contain a planar or heteroaromatic ring system that wedges itself between the double 
helix of DNA, causing a distortion in its structure.79 This change in structure prevents polymerases 
and other enzymes involved in DNA replication and transcription to function. Several naturally 
occurring antibiotics fall into this class, including dactinomycin and doxorubicin (Fig. 1.8). Other 
anthracyclines used are mitoxantrone and amsacrine (Fig. 1.8). 
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Non-Intercalating Anticancer Agents 
These anticancer drugs generally inhibit topoisomerses, which are enzymes that regulate the 
unwinding and rewinding of DNA during DNA replication. The camptothecins (irinotecan) are a group 
of naturally occurring cytotoxic alkaloids that target topoisomerase I, while the podophyllotoxins 
(etoposide and teniposide) target topoisomerase II and prevent the resealing of DNA strands during 
DNA replication (Fig. 1.9).73, 80  
 
Fig. 1.9: Examples of non-intercalating agents currently available 
 
Alkylating Agents 
These are highly electrophilic molecules that form strong covalent bonds with the nucleophilic 
nitrogenous DNA bases. Some drugs are able to cross-link between the DNA strands if they have two 
alkylating groups. Alkylating agents are highly carcinogenic compounds due to their ability to 
damage DNA in both normal and cancerous cells.81 Cisplatin and its analogues (carboplatin and 
oxaliplatin) are well-known drugs from this class (Fig. 1.10). Other frequently used alkylating agents 
are the nitrogen mustards, in particular, uracil mustard.82 Cyclophosphamide, a prodrug, is another 
frequently used alkylating agent which is converted to its active form in the liver by cytochrome 
P450 enzymes.58     
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1.2.2.2 Anticancer Drugs that indirectly act on DNA  
This class of drugs act by targeting the enzymes involved in DNA synthesis and repair mechanisms. 
These inhibitors are also called antimetabolites and pose as nitrogenous bases that become the new 
building blocks of DNA. Research done on this class of compounds suggests that these drugs inhibit 
the S phase of the cell cycle, resulting in programmed cell death.83 There are several enzymes that 
are involved in the synthesis of DNA and, in principle, can be potentially inhibited. One of the most 
commonly used drugs from this class are the dihydrofolate reductase inhibitors such as 
methotrexate (Fig. 1. 11).84 The thymidylate synthase is inhibited by 5-fluorouracil; this enzyme is 
responsible for the biosynthesis of thymidine, a DNA nucleoside (Fig. 1.11).85 Inhibitors of 
ribonucleotide reductase, adenosine diaminase and DNA polymerases are clinically used to block 
DNA synthesis and trigger apoptosis.     
 
Fig. 1.11: Structure of methotrexate and 5-fluorouracil 
 
1.2.2.3 Drugs that act on Signalling Pathways 
Traditional cancer therapies involve administering drugs that are often cytotoxic to both normal and 
cancerous cells. As such, selectivity is dependent on the preferential accumulation and increase in 
concentration of the drugs within cancerous cells as opposed to normal cells. The protein kinase 
inhibitors are a broad range of inhibitors that prevent phosphorylation of specific amino acids, which 
blocks signal transduction, leading to inactivation of transcription factors. PTK787 (vatalanib) and 
SU5416 (semaxanib) are examples of kinase inhibitors while flavopiridol and (R)-reoscovitine are 
examples of cyclin-dependent inhibitors (Fig. 1.12).73  
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1.3 Chromones – Introduction and Antitumour Activity 
Introduction 
Chromones, derived from the Greek word ‘chroma’ meaning colour, are a group of naturally 
occurring compounds that are widely distributed in nature, especially in the plant kingdom. The 
chromone ring system, or 1-benzopyran-4-one (Fig. 1.13), is a core fragment in many flavonoids. 
Flavonoids are a major class of secondary metabolites found in vascular and in some nonvascular 
plants.86 Many flavonoids have been reported to possess medicinal properties, including  
anti-HIV, antibacterial, anti-inflammatory and anticancer activities.87–95 
 
Fig. 1.13: Structure of the chromone scaffold  
 
The rigid bicyclic chromone fragment has been classified as a privileged substructure in drug design 
and discovery.96 Privileged substructures are components of a compound or a molecular framework 
that are able to provide ligands for diverse receptors in biological systems.96, 97 The collective term 
‘chromones’ will be used in this discussion as a reference to chromone derivatives. Although a 
variety of chromone derivatives possess biological activity, only a few are presently used as 
therapeutic agents. The first chromone used in its pure form clinically was khellin  
(Fig. 1.14). This compound was originally extracted from the seeds of the Ammi visnaga plant and 
used as a diuretic to relieve renal colic in Ancient Egypt, but is now more commonly used for the 
management of vitiligo, a pigmentation disorder.98–100 Other clinically used drugs containing the 
chromone moiety include sodium cromoglycate (Lomudal®, Sanofi-Aventis), used as a mast cell 
stabilizer in treating and managing allergic and exercise-induced asthma; and diosmin, marketed as 
Daflon®, a phlebotropic drug in the treatment of venous diseases and haemorrhoids.101–104 
 













Chapter One – Introduction and Background  
15 
 
Several naturally occurring benzopyran derivatives are potentially useful antitumour agents due to 
their ability to inhibit protein kinase-dependent signal transduction pathways, specifically tyrosine 
kinases.105 Tyrosine kinase receptors are membrane-bound proteins that allow transfer of a 
phosphate group from ATP to a tyrosine residue, which in turn triggers a signalling cascade that 
results in activation of transcription factors and cell proliferation.73 These enzymes act like ‘on/off’ 
switches in cells, controlling the activation of transcription factors. A faulty tyrosine kinase that is 
continuously switched ‘on’ results in continuous activation of transcription factors which may lead to 
the initiation and/or progression of cancer.75 
Some naturally occurring chromones such as genistein, quercetin, apigenin and myricetin, are known 
to inhibit tyrosine kinases (Fig. 1.15).106–109 Genistein, a 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-
chromen-4-one, is a highly specific tyrosine kinase inhibitor. Reports suggest that genistein inhibits 
epidermal growth factor (EGF) response in cultured A431 (human epidermoidal) cancer cells.107 EGF 
is responsible for stimulation of cell growth, proliferation and cell differentiation; therefore 
interruption of its activity results in inhibition of the cell cycle.110 Studies conducted by Papazisis and 
co-workers demonstrated that genistein has a role in triggering apoptosis and promotes cell cycle 
arrest in γ-irradiated K562 leukaemia cell lines.111 This further suggests that the chromone 
pharmacophore could be an attractive template for the development of potential antitumour and 
antiplasmodial agents.  
 
Fig. 1.15: Examples of chromone-based compounds that have exhibited kinase inhibition activity 
 
Antitumour Activity of Chromones 
There are many reports of compounds that contain the chromone substructure possessing 
antitumour activity.112–117 Recently, Dyrager and co-workers described the synthesis and antitumour 
activity of chromone-based kinase inhibitors that target the p38α MAP kinase enzyme.113 They 













Chapter One – Introduction and Background  
16 
 
site of the p38α MAP kinase enzyme. Fig. 1.16 depicts the suggested interactions between the 
substituents on the chromone ring and the ATP binding pocket.  
 




As stated in section 1.2, compounds that inhibit the signal transduction cascade lead to programmed 
cell death, resulting in the inhibition of growth of cancerous cells. This led to Forghieri and  
co-workers using a chromone substructure as a low molecular weight tyrosine phosphatase 
inhibitor.118 Another example of the chromone substructure in antitumour research is  a 
formylchromone derivative (6-(biphenyl-4-yl)-4-oxo-4H-chromene-3-carbaldehyde) designed by 
Shim and colleagues as a potential tyrosine phosphatase inhibitor (Fig. 1.17).112 There are numerous 
reports on the chromone substructure being involved in antitumour activity; however, only selected 
examples were highlighted here. Reports on the chromone substructure having antiplasmodial 
activity are, however, limited.119 Kunert et al reports the moderate antiplasmodial activity of a 
bischromone extract isolated from Selaginella bryopteris.120  
These privileged structures have displayed favourable antitumour activity; therefore their 


















Fig. 1.17: (a) Most potent chromone described in Forghieri et al
118
, (b) most active compound by Shim et al
112
, 




1.4 Hybrids – Background/Introduction 
Hybrid molecules are comprised of two or more molecular components, referred to as 
pharmacophoric units, which are covalently linked together.121 Hybrids differ from prodrugs; which 
are compounds that are administered as pharmacologically inactive agents that are converted to 
their active forms by bio-activation or metabolic processes.122 In the light of increasing emphasis on 
combination therapy in treating diseases, especially in the treatment of malaria, one can argue that 
it may be advantageous to combine two drugs into a single molecular entity (Fig. 1.18). Among the 
numerous benefits of hybrids include their potentially lower cost of synthesis and lower risk of 
adverse drug-drug interactions compared to multi-component drugs.123 This type of design is 
sometimes referred to as ‘covalent bitherapy’.121 When designing a hybrid molecule, the following 
should be taken into account: issues of the individual component’s association with drug resistance, 
potency, solubility, mode of administration, pharmacokinetics, metabolism and toxicity.121, 124  
 
Fig. 1.18: Illustration of a hybrid drug: molecular components A and B being linked by a Linker 
 
There are numerous forms in which a hybrid molecule can be presented: 
 Both components A and B in the active form 
 Either component A or B in the active form while the other is in a prodrug form 
 Both components A and B in the prodrug form125 
Another key consideration in hybrid drug design is the choice of linker, as the nature of the linker 
and the distance between the pharmacophores can play an essential role in the pharmacokinetics of 
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dissociation upon administration or to remain intact until being cleaved at the target. These 
molecules can be linked in various ways, and depending on the rationale behind the design, hybrid 
molecules can be classified into the following categories:  
 Directly Linked – the pharmacophores are connected via a functional group of each 
molecule, which produces a highly enzymatically hydrolyzable functional group, such as an 
ester, carbamate or amide.126 An example of this is estramustine (below), a hybrid between 
estradiol and mechlorethamine linked via an ester bond.127  
 
 
 Spacer Linked – the pharmacophores are connected via either a cleavable or non-cleavable 
linker. A non-cleavable linker is generally a non-hydrolyzable chemical bond; this is 
exemplified by the trifluoromethylartemisinin-mefloquine hybrid.121, 128 In contrast, the 
cleavable linker is generally a hydrolyzable bond that can be hydrolyzed by plasma enzymes, 
as seen in NO-Aspirin. 126 
 
 
 Fused – the pharmacophores are connected via a very short linker that allows the two 
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 Merged – the pharmacophores have merged using common functional groups on the two 
molecules to produce a smaller compound; this can be seen in the anti-inflammatory 




1.4.1 Examples of Hybrid Drugs in Malaria 
4-Aminoquinoline-1,2,4-Trioxane-Based Hybrids 
Cosledan et al reported the synthesis and development of trioxaquine as a potential antimalarial 
drug candidate.130 Trioxaquines are hybrid compounds comprising of a 4-aminoquinoline and  
1,2,4-trioxane linked to a cyclohexyl moiety by a spiro carbon atom. These molecules were created 
to have dual modes of action, as the trioxane pharmacophore can be involved in haeme alkylation 
while the 4-aminoquinoline nucleus can be used in haeme stacking.131 Compound 
PA1103/SAR116242 (Fig. 1.19) was selected for preclinical development as it exhibited high potency 
against several chloroquine-sensitive and -resistant strains of P. falciparum. The hybrid was found to 
be effective in humanized mice infected with P. falciparum and displayed a good drug profile 
(absorption, metabolism and safety parameters).130  
Endoperoxide-Quinoline-Based Hybrids 
Walsh and co-workers designed and prepared an artemisinin-quinine hybrid in which 
dihydroartemisinin was directly linked to a carboxylic acid derivative of quinine via an ester linkage 
(Fig. 1.19).132 The hybrid was found to have potent activity against the drug susceptible 3D7 and drug 
resistant FcB1 P. falciparum strains. To determine if the covalent linker between the two 
pharmacophores is required, the two pharmacophores (dihydroartemisinin and quinine) were tested 
individually and as a 1:1 molar ratio mixture. It was observed that the chemically-linked hybrid had 
superior activity. The mode of action of this drug is unknown, but it was postulated that the hybrid is 
cleaved in vitro. However, this has raised concerns over the comparison of the activities of the 
hybrids with their individual components as the individual components are not identical to the 
pharmacophore that each represents due to the chemical alterations that were done in order to 


















Recently, a series of 4-aminoquinoline-pyrimidine based hybrids were synthesized by Manohar and 
colleagues as potential antimalarials.133 The 4-aminoquinoline and pyrimidine scaffolds were 
connected via a flexible linear diaminoalkane linker. The compounds were evaluated for their 
antiplasmodial activities against both CQ-sensitive D6 and CQ-resistant W2 strains of P. falciparum, 
with some hybrids possessing good in vitro potency. The hybrid with N-ethyl piperazine as a 
substituent on the pyrimidine scaffold had the greatest in vivo potency in the P. berghei malaria 
mouse model (Fig. 1.19). The results indicate that a synergistic effect is seen in the covalent binding 
of the 4-aminoquinoline to the pyrimidine substructure.133  
 
Fig. 1.19: Structure of hybrid molecules designed as potential antimalarial agents 
1.4.2 Examples of Hybrid Drugs in Cancer 
Estramustine  
Estramustine (Emcyt®, manufactured by Pfizer) is the only hybrid drug used clinically for the 
treatment of prostate cancer (Fig. 1.20) and is administered as a phosphate salt to enhance water  
solubility.126, 134, 135 The steroid, estradiol, is connected to a nitrogen mustard-carbamate via an ester 
linkage. The hybrid interacts with cellular microtubules and inhibits the G2 phase in the cell cycle 
and thus inhibits DNA replication. To circumvent the emergence of resistance to this drug studies are 
in progress to optimize the use of estramustine in combination therapy.126, 136 
Artemisinin-Acridine-Based Hybrids  
Jones and co-workers reported the synthesis of artemisinin-acridine hybrids in which an artemisinin 
substructure was covalently linked to 9-diaminoalkyl-6-chloro-2-methoxyacridines (Fig. 1.20).137 The 
hybrids exhibited appreciable antitumour activity against HL60 (human leukemia cells), MDA-MB-
231 (metastatic human breast cells) and MCF-7 (human breast cells) cancer cell lines. It was 
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pharmacophore in the antitumour assays using flow cytometry, it was reported that the most potent 
hybrids appeared to induce apoptosis in HL60 cancer cells, which indicated that cell arrest occurred 
during the G1 phase of the cell cycle.137   
2-Phenylbenzofuran-Imidazole-Based Hybrids 
Yang et al. reported the synthesis of directly-linked hybrids that contain the 2-phenylbenzofuran and 
imidazole moieties.138 Both the pharmacophores (benzofuran and imidazole) have potent cytotoxic 
activities and thus covalently linking them into a single entity was thought to enhance the potency. A 
small library of compounds was synthesized to determine the structure-activity relationship of these 
hybrids, and it was evident from the antitumour testing that one hybrid displayed potent activity in 
human tumour cell lines (Fig. 1.20).138  
 
Fig. 1.20: Examples of hybrid molecules designed as antitumour agents 
 
There are numerous reviews available discussing, in detail, the design and development of hybrid 
molecules as potential therapeutics for other diseases. However, only a few were discussed here in 
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1.5 Aims and Objectives 
Overall Aim:  
The general objective of this research is to identify novel chromone-based hybrid molecules with in 
vitro activity against the malaria parasite in the chloroquine-sensitive (CQS) D10 and NF54 strains 
and the chloroquine-resistant (CQR) K1 strain of P. falciparum and the oesophageal WHCO1 cancer 
cell line.  
 
Objectives: 
 To synthesize chromone-based hybrids and investigate their structure-activity relationship 
(SAR) as antiplasmodial and antitumour agents 
 Determination of the contribution of pharmacophoric units to the pharmacological activity 
of hybrids by screening appropriate intermediates, i.e. screening the respective individual 
pharmacophores and 1:1 molar ratio mixtures 
 In-silico and in vitro profiling of synthesized compounds for solubility  
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Chapter Two – Design, Synthesis and Biological Evaluation of Chromone-Aminoquinoline Hybrids 
2.1 Introduction 
This chapter describes the design, synthesis and characterization of an exploratory series of novel 
compounds obtained by the hybridization of an antimalarial and an anticancer pharmacophore. The 
pharmacophores of choice are the 4-aminoquinoline and chromone motifs. The synthetic 
procedures used were based on standard chemistry protocols. The resultant structurally related 
molecules formed the basis of a more focused structure-activity relationship (SAR) study. All 
analogues synthesized were evaluated for their in vitro antiplasmodial and antitumour activities. 
Furthermore, testing for antimycobacterial activity was also carried out in addition to various 
physicochemical property profiling.  
2.2 Rationale for the Synthesis of Chromone-Aminoquinoline Hybrids 
A pharmacophore is described as ‘a molecular framework that carries the essential features 
responsible for a drug’s biological activity’.1 The use of pharmacophore hybridization is thought to be 
analogous to conventional combination therapy, with the exception that the two drugs are now 
covalently-linked and are available as a single entity.2 This approach offers a large SAR study which 
precludes the need for large libraries, drastically shortening the time needed to identify potential 
leads.3 Covalently linking two distinct chemical moieties with different modes of action to produce a 
hybrid is now a commonly used strategy in the discovery and development of antimalarial drugs.4  
 
In this work, hybrids were developed using cleavable amide and non-cleavable alkyl linkers. 
Additionally, the concept of a compound having superior activity to its individual components 
through a synergistic or additive effect was investigated by evaluating the activity of hybrids and 
their precursors. In principle, the biological activities are envisaged to be maximized by the 
incorporation of the chromone core, an anticancer pharmacophore, to the 4-aminoquinoline moiety, 
an antimalarial pharmacophore, via a covalent linker at positions 2 and 3 of the chromone ring. 
Some key structural and chemical features targeted for investigation through SAR studies are 
summarized in Fig. 2.1. One of the objectives of this project was to evaluate the linker between the 
pharmacophores. For this, two types of linkers were chosen; an alkyl (non-cleavable) linker and an 
amide (cleavable) linker; where the latter has the potential to be hydrolyzed in vivo to produce the 
individual pharmacophores. Various electron-withdrawing groups such as bromo, chloro, and fluoro 
groups, and electron-donating groups and electron-releasing groups such as methoxy and methyl 
groups, were added at position 6 of the chromone ring to study the electronic properties of the 
chromone ring and its effect on antiplasmodial and antitumour activity. In the synthesis of alkyl- and 
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first. The reactivity, synthesis and characterization are described below, followed by the synthesis 
and characterization of the target hybrid compounds.  
Fig. 2.1: Outline of target compounds 
 
2.3 Aminoquinolines – Introduction, Reactivity, Synthesis and Characterization  
Introduction 
Aminoquinolines consist of a quinoline scaffold, which is prevalent in a variety of pharmacologically 
active antimalarials (Fig. 2.2).5 Chloroquine (CQ) is perhaps one of the most recognizable drugs from 
this group, along with other antimalarials including amodiaquine, piperaquine, primaquine, quinine 
and mefloquine. The quinoline nucleus has been found to inhibit haeme polymerization and 
haemozoin formation.6 This in turn leads to the intraparasitic accumulation of free haeme, which is 
highly toxic to the malaria parasite as highlighted in chapter one. 
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Previous SAR studies conducted on chloroquine and closely related 4-aminoquinoline antiplasmodial 
compounds report that for optimal antiplasmodial activity in CQ-sensitive (CQS) and CQ-resistant 
(CQR) strains of P. falciparum, the following structural features must be present: 
 a quinoline ring, with no alkyl substitutions attached;  
 a halogen at position 7 of the quinoline ring, except for fluorine; 
 a nitrogen atom at position 1 of the quinoline ring that is able to undergo protonation; and 
 a protonatable nitrogen atom at the end of the side chain attached to the quinoline ring at 
position 4.7, 8 
 
Egan and co-workers established that the aminoquinoline ring is essential for antiplasmodial activity, 
as the motif associates with haematin.7 They also reported that having a chloro, bromo or iodo 
group at position 7 of the aminoquinoline ring improves antiplasmodial activity.7 β-haematin 
inhibition studies conducted by Egan and co-workers have found that aminoquinolines that have an 
electron-donating group at C7 of the ring have the highest inhibition rates.
8 Research has suggested 
that if a compound can inhibit β-haematin formation, it has the potential to display excellent 
antiplasmodial activity. Further studies have suggested that the length of the alkyl group between 
the two nitrogen atoms on the 4-amino side chain must be between 2 and 4 carbon atoms, or 
between 10 and 12 carbon atoms to maintain activity against CQR strains of P. falciparum.9 The 
inclusion of protonatable nitrogen atoms at position 1 of the aminoquinoline ring and at the end of 
the side chain attached at position 4 is required for vacuolar accumulation (Fig. 2.3). These points 
validate the use of the aminoquinoline scaffold in the search of new antimalarials, as compounds 
having this moiety have had high levels of success in the treatment and prophylaxis of malaria. 
Another key characteristic of these compounds is that they have relatively easy and cheap synthetic 
routes; additionally, drug resistance occurs due to the inability of the drug to access the target site 
and not from structural changes to the target.6, 10 
 




















Quinolines are heterocyclic rings produced by the fusion of benzene and pyridine rings. Quinoline 
chemistry is similar to that of benzene and pyridine wherein the benzene ring favours electrophilic 
substitution and the pyridine ring favours nucleophilic substitution.11 These compounds are 
generally more π-deficient due to their mesomeric and inductive effects which are attributed to the 
nitrogen atom within the ring (Fig. 2.4). This effect is most evident at C2 and C4 due to the close 
proximity of the nitrogen atom. The reactivity at these positions can be further increased by the 
introduction of electron-withdrawing groups, such as halogens, on the ring.  
 
Fig. 2.4: Illustration of the mesomeric and inductive effects of the nitrogen atom on the quinoline ring  
 
Synthesis of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine, SN08 
The primary amine, SN08, was prepared by stirring 4,7-dichloroquinoline in ethylene diamine for  
1 hour at 100 oC and then increasing the temperature to 140 oC for a further 4 hours (Scheme 2.1). 
SN08 was isolated as a pale-yellow solid with a satisfactory yield. 
 
Scheme 2.1: Reagents and conditions: i. Ethylene diamine (6.0 eq), 100 – 140 
o
C, 5 h 
 
The reaction follows a nucleophilic aromatic substitution route (SNAr) where the addition of a 
nucleophile is followed by the elimination of the leaving group (Fig. 2.5). Ethylene diamine acts as 
the nucleophile, attacking the carbon atom at position 4 of the heteroaromatic ring. The carbanion is 
resonance-stabilized by the delocalization of the negative charge within the ring. Subsequent 





















Spectroscopic Analysis of 4-aminoquinoline derivative 
The synthesized quinolines exhibit a unique pattern in their 1H and 13C NMR spectra, with the 
methylene protons resonating upfield between 2.98 and 3.44 ppm in the 1H NMR spectrum  
(Fig. 2.6). Analysis of the 1H NMR spectrum depicts the vicinal coupling of H1 to H2 and H3 to H4 with J 
values of 5.7 and 9.0 Hz respectively; these are consistent with those reported in the literature.12 H4 
was seen as a doublet of doublet (dd) due to its coupling to H3 and its additional long-range coupling 
to H5. In the 
13C NMR spectrum of SN08, eleven signals were observed corresponding to the total 
number of carbon atoms in the molecule, with the carbon para to the nitrogen atom within the 
heterocyclic ring, resonating at 152.8 ppm as the most downfield signal. In the infrared spectrum, 
which was recorded in KBr, there is a distinct band at 1578 cm-1, corresponding to the imine 
stretching frequency. The uncorrected melting point of SN08 was found to be in the range of 128 – 
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2.4 Chromone-Aminoquinoline Hybrids 
The synthesis of the chromone-aminoquinoline hybrids was accomplished by the coupling of a 
chromone derivative to the aminoquinoline nucleus. Described below is the reactivity of chromones, 
followed by the synthesis and characterization of the target compounds.  
Chromones – Introduction and Reactivity 
The chromone substructure is a privileged motif in drug discovery and thus can be used in the search 
of potentially useful chemotherapeutic agents.13 Chromones are heterocyclic molecules that are 
derivatives of benzopyran with a substituted keto group on a γ-pyrone ring. They are able to 
undergo a wide range of chemical reactions with nucleophiles and electrophiles. Typically, 
nucleophiles attack at positions 2 and 4 of the heterocyclic ring; however, attacks at position 2 lead 
to the opening of the pyrone ring resulting in the loss of the C2-C3 π bond. Opening of the chromone 
ring can also be achieved by treatment with aqueous alkali.14 Electrophilic reactions normally occur 
at O1, C3 or the carbonyl oxygen, due to the accumulation of electron density of the heteroatoms 
(Fig. 2.7).11 The pyrone ring, on the other hand, is relatively unreactive towards electrophiles as 
electrophilic reagents such as strong acids tend to protonate the pyrone ring thereby inactivating 
it.15 The presence of a halogen or triflate allows chromones to be used as substrates in various 
coupling reactions to introduce alkyl or aryl substituents.  
  
Fig. 2.7: Illustration of the reactivity of chromones 
 
2.4.1 Chromone-Aminoquinoline Alkyl-Linked Hybrids, Series 1 
The aminoquinoline nucleus was linked via an alkyl chain to position 3 of the chromone moiety to 
produce Series 1. This was prepared using the primary amine, SN08, and an aldehyde in a reductive 
amination reaction step. To achieve this, chromone-3-carbaldehydes were synthesized; the synthesis 
and characterization of these aldehydes is described below.    
2.4.1.1 Synthesis and Characterization of Chromone-3-Carbaldehydes 
A series of substituted chromone-3-carbaldehydes, SN18 – SN23 and SN83-1 – SN95-1, were 
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reaction.16 Substituted 2-hydroxyacetophenones were treated with phosphorus oxychloride (POCl3) 
in anhydrous N,N-dimethylformamide (DMF) at low temperature (Scheme 2.2). The crude 
compounds were recrystallized from acetone to afford the pure aldehydes (Table 2.1). 
 




Table 2.1: Isolated yields, molecular ion peaks and melting points of chromone-3-carbaldehydes  
 
Code R Yield (%) 
[M]+ Melting 
Point (oC) Expected    Found 
SN18 H 61 174.0 174.0 144 – 146 
SN19 Cl 89 207.9 207.9 166 – 167 
SN20 Br 90 251.9 251.8 158 – 160 
SN21 F 66 192.0 192.1 146 – 149 
SN22 OCH3 56 204.1 203.9 145 – 148 
SN23 CH3 67 188.1 187.9 156 – 159 
 
In a Vilsmeier-Haack reaction, N,N-dimethylformamide and phosphorus oxychloride are used in 
conjunction to produce a chloroiminium ion, a carbon electrophile. The amide functional group in 
DMF reacts with POCl3, which removes the amide oxygen and replaces it with a chlorine atom; this 
step is unfavourable except for the formation of the strong phosphorus-oxygen bond. The iminium 
cation then reacts with the acetophenone enolate, which is generated by the protonation of the 
carbonyl oxygen. This produces a chromen-4-one, which attacks another iminium cation to produce 
a cationic intermediate. Subsequent hydrolysis and proton transfer (P.T.) adds a formyl group on  

















Fig. 2.8: Proposed mechanistic route for the formation of chromone-3-carbaldehydes 
 
Spectroscopic Analyses of Chromone-3-carbaldehydes 
In the 1H NMR spectra of these compounds, the distinctive signal above 10 ppm confirms the 
presence of the aldehyde proton. The proton adjacent to the oxygen in the chromone ring resonates 
at 8.5 ppm due to the heteroatom and the neighbouring double bond. The remaining protons on the 
chromone ring (for further details, please see chapter five) correspond to values reported in the 
literature.16 Further indication of the presence of the formyl group was seen in the infrared 
spectrum recorded in KBr, which showed two separate absorption bands at 1600 cm-1 due to the 
two carbonyl functional groups within the molecule. Mass spectra analyses indicated the presence 
of the molecular ion peaks of the aldehydes. Once the aldehydes were synthesized, the next step 
was the synthesis of the covalently-linked chromone-aminoquinoline hybrids. 
2.4.1.2 Synthesis and Characterization of Alkyl-Linked Hybrids, Series 1 
These target compounds were prepared by reductive amination of the chromone-3-carbaldehydes 
with SN08. The amine and aldehydes were stirred in anhydrous dichloromethane and methanol at 
room temperature to generate the imines in situ.17 The formation of the imine was detected by the 
disappearance of the aldehyde spot on TLC. Once the disappearance of the starting material was 
observed, sodium triacetoxyborohydride [NaBH(OAc)3] was added to reduce the imine and produce 

















Scheme 2.3: Reagents and conditions: i. SN18 – SN23 (1.0 eq), DCM, CH3OH, N2, RT;  
                                               ii. NaBH(OAc)3 (3.0 eq), RT, 16 h 
 
Spectroscopic Analyses of Alkyl-Linked Hybrids 
The 1H NMR spectrum of SN25 is presented in Fig. 2.9, illustrating the general pattern of the 
covalently-linked hybrids. The disappearance of the aldehyde proton signal of the chromone-3-
carbaldehyde was a clear indication that the reductive amination had been successful. In addition, 
the appearance of a singlet at 3.18 ppm was assigned to the newly-formed methylene group, H5. The 
protons on the aminoquinoline nucleus remain at relatively similar chemical shifts as observed 
previously, with the exception of the signals for H6 and H7, which have moved further downfield 
from 2.98 and 3.44 ppm to 3.52 and 3.62 ppm, respectively, due to the attachment to the chromone 
scaffold. The COSY spectrum confirmed the correlation and coupling between the aromatic protons. 
The 13C NMR spectra indicated twenty-one carbons for the alkyl-linked hybrids except for SN27 and 
SN28, which had twenty-two carbons due to the methoxy and methyl groups on their chromone 
structures. Analyses of the spectroscopic data indicated the successful syntheses of the chromone 
alkyl-linked aminoquinoline hybrids.    
Table 2.2: Isolated yields, molecular ion peaks and melting points of Alkyl-Linked Hybrids  
 
Code R Yield (%) 
[M]+ Melting 
Point (oC) 
 Expected      Found 
SN31 H 50 379.1 379.0 81 – 83  
SN24 Cl 65 413.1 412.8 96 –100  
SN25 Br 75 457.0 458.5 122 – 125 
SN26 F 60 397.1 395.1 117 – 119 
SN27 OCH3 41 409.1 409.1 94 – 98 





















H NMR of SN25 in DMSO-d6 at 400 MHz 
2.4.2 Chromone-Aminoquinoline Amide-Linked Hybrids, Series 2 and Series 3 
Series 2 and 3 contain the amide-linked chromone-aminoquinoline hybrid compounds; these were 
synthesized via amide coupling procedures involving a coupling agent, EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide), with SN08 and the chromone carboxylic acids. The carboxylic 
acids in these cases were the chromone-3-carboxylic acids and chromone-2-carboxylic acids. The 
synthesis and characterization of these acids are described below followed by the synthesis and 
characterization of the hybrids.  
2.4.2.1 Synthesis and Characterization of Chromone-3-Carboxylic Acids 
A series of chromone-3-carboxylic acids, SN11, SN29, SN38, SN40 – SN42 and SN83-2 – SN95-2, 
were prepared using the Lindgren oxidation route (Scheme 2.4). Lindgren oxidation involves the 
selective oxidation of aldehydes to carboxylic acids using a mixture of water and a polar solvent.18 
Sodium chlorite was used as the oxidizing agent with sulfamic acid as the scavenger to remove any 
by-product, specifically the hypochlorite generated in the reaction. This procedure works efficiently 
when the chromone-3-carbaldehydes were vigorously stirred in a mixture of dichloromethane and 
distilled water for 4 – 6 hours. Recrystallization of the crude material from methanol produced the 
pure acids in high yields. A summary of the carboxylic acids can be seen in Table 2.3, with the 


















Scheme 2.4: Reagents and conditions: i. NaClO2 (6.0 eq), NH2SO3H (8.0 eq), DCM, H2O, RT, 4 – 6 h 
 






Point (oC) Expected     Found 
SN11 H 78 190.0 190.0 147 – 150 
SN29 Cl 77 223.9 223.9 212 – 215 
SN38 Br 56 267.9 267.9 175 – 178 
SN40 F 85 208.0 208.0 222 – 224 
SN41 OCH3 81 220.0 220.0 155 – 157 
SN42 CH3 77 204.2 204.0 225 – 228 
 
Spectroscopic Analyses of Chromone-3-carboxylic acids 
Distinctive features of carboxylic acids are the broad downfield singlets in the 1H NMR spectra, 
generally seen at 13 ppm. It was also observed that there was a downfield shift of the chromone 
proton due to the acidic group. The remaining protons on the ring resonate in similar chemical 
environments as their corresponding aldehydes. In comparing the 13C NMR spectra of the chromone-
3-carbaldehydes and chromone-3-carboxylic acids, the signal for C4 shifted upfield, whereas the 
carboxylic acid carbon resonated downfield when compared to the aldehyde carbon. Analysis of the 
infrared spectrum of SN29, 6-chloro-4-oxo-4H-chromene-3-carboxylic acid, indicated two carbonyl 
stretches at 1625 and 1739 cm-1 and a broad band at 3443 cm-1 corresponding to the O-H stretch. 
These analyses and the mass spectrometry data confirm the successful oxidation of the aldehydes 
into chromone-3-carboxylic acids.  
2.4.2.2 Synthesis and Characterization of Chromone-2-Carboxylic Acids 
The synthesis of the chromone-2-carboxylic acids, SN68 – SN72, was accomplished by the Baker-
Venkataraman rearrangement using diethyl oxalate and sodium ethoxide followed by an acid 

















Scheme 2.5: Reagents and conditions: i. Diethyl oxalate (1.1 eq), NaOEt, N2, 95 
o
C, 2h;  
                                                             ii. Glacial acetic acid, HCl (conc.), 95 
o
C, 2h   
 
This rearrangement proceeds via an enolate intermediate formed between the  
2-hydroxyacetophenone and diethyl oxalate (Fig. 2.10). This is followed by an acyl transfer in sodium 
ethoxide, which was generated in situ to generate the 1,3-diketone, which was not isolated but used 
as a crude mixture. Ring closure occurred when the crude mixture was treated with concentrated 
hydrochloric acid and glacial acetic acid. Recrystallization from glacial acetic acid afforded the 
chromone-2-carboxylic acids as pure off-white/grey solids with moderate yields. These acids had 
poor solubility in chlorinated and alcoholic solvents as opposed to their chromone-3-carboxylic acid 
counterparts.  
 
Fig. 2.10: Proposed mechanistic route for the formation of chromone-2-carboxylic acids, SN68 – SN72 
 
Spectroscopic Analyses of chromone-2-carboxylic acids 
Due to the poor solubility of the acids in chloroform, 1H NMR spectra were recorded in deuterated 
dimethyl sulfoxide. As a result, the carboxylic acid proton was not observed presumably due to the 
rapid exchange with water present in DMSO-d6. The other signals represent the remaining protons 
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spectra confirmed ten carbons for the carboxylic acids except for SN72, which had eleven carbons 
due to the methoxy group on the chromone motif. Additionally, two downfield signals at 164 and 
178 ppm in the spectra corresponding to the two carbonyl carbon atoms were observed. Further 
confirmation of the successful synthesis of the chromone-2-carboxylic acids was the identification of 
the molecular ion peaks in the mass spectrometry analyses (Table 2.4). It was observed that the 
melting points of the chromone-2-carboxylic acids were generally much higher than those of the 
chromone-3-carboxylic acids as reported in literature.23 






Point (oC) Expected    Found 
SN68 H 72 190.0 190.0 252 – 255 
SN69 Cl 60 223.9 223.9 242 – 245 
SN70 Br 60 267.9 267.7 263 – 265 
SN71 F 28 208.0 207.8 243 – 245 
SN72 OCH3 62 220.0 219.9 279 – 281 
 
2.4.2.3 Synthesis and Characterization of Amide-Linked Hybrids, Series 2 and 3 
The 4-aminoquinoline derivative was attached via an amide linker to position 3 (Series 2) and 
position 2 (Series 3) on the chromone ring (Scheme 2.6).  
 
Scheme 2.6: Reagents and conditions: i. EDC (1.3 eq), HOBt (1.3 eq), SN08 (1.5 eq), DMAP (0.5 eq),  
DCM, DMF, N2, 16h 
 
The amide bond was formed by the condensation of the primary amine, SN08, with the carboxylic 
acids in the presence of EDC. EDC was used here as the hydrochloride salt and therefore required 
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used as a catalyst. The mechanism involves the deprotonation of the carboxylic acid by EDC, 
followed by nucleophilic attack by the carboxylate onto the carbodiimide. This allows for the 
formation of an isourea intermediate. HOBt (N-hydroxybenzotriazole) intercepts the activated ester 
intermediate to displace a highly water soluble urea group (1-(2-(dimethylamino)ethyl)-3-ethylurea) 
and suppresses any racemization that may take place. The production of urea as a by-product 
accelerates the forward reaction, allowing the terminal amine group on SN08 to attack the HOBt 
ester and produce the amide product.11 A detailed mechanism is shown in Fig. 2.11.  
 
Fig. 2.11: Mechanism of formation of amide-linked hybrid compounds 
 
These coupling reactions were conducted in either DMF or a mixture of DCM/DMF as solvents, 
depending on the solubility of the acid used. The purification was accomplished using a gradient of 
DCM:MeOH as the eluent on silica gel to obtain the target compounds in varying yields (Table 2.5).  
Spectroscopic Analyses of Series 2 and Series 3 
SN74 will be used as a representative of the amide-linked hybrid compounds and will thus be 
analysed in detail. The 1H NMR spectrum of SN74 (Fig. 2.12) confirmed the formation of the amide 
hybrid as there was a downfield shift of the aliphatic protons (H6 and H7) from 2.98 and 3.44 ppm in 
SN08 to 3.67 and 3.74 ppm in the hybrid. The aromatic signals remain in relatively similar chemical 
shift environments and produced similar coupling constants as in their precursors, except for H1, 
which shifted downfield as it is now adjacent to the amide bond and not the electron-withdrawing 
carboxylic acid. Analysis of the COSY spectrum indicated the position of the signals produced by the 
protons attached to the nitrogens; Ha was found to have vicinal coupling with H6 and Hb with H7, both 













Chapter Two – Design, Synthesis and Biological Evaluation of Chromone-Aminoquinoline Hybrids 
41 
 
carbons shifted significantly upfield, from 40.8 and 46.1 ppm in SN08 to 38.4 and 41.9 ppm, due to 
the amide bond formation. The carbon atoms on the aminoquinoline and chromone nucleus were 
found to resonate in similar chemical shift environments as those in their respective starting 
compounds. An additional indication of successful synthesis was that the total number of signals was 
equal to the number of carbon atoms in the structure. The other amide-linked hybrids follow a 
similar trend in their spectra. Mass spectrometry analyses further indicated successful synthesis of 
the amide-linked hybrid series.  
Table 2.5: Isolated yields and molecular ion peaks of amide-linked hybrid molecules  
 









Expected    Found Expected    Found 
SN44 H 49 393.1 393.0 SN74 H 46 393.1 393.0 
SN48 Cl 46 427.1 428.0 SN75 Cl 70 427.1 427.0 
SN54 Br 36 470.9 472.1 SN76 Br 72 470.9 472.8 
SN55 F 62 411.1 410.8 SN77 F 65 411.1 410.9 
SN56 OCH3 46 423.1 422.8 SN78 OCH3 55 423.1 422.8 
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2.5. Physicochemical Properties and Biological Evaluation  
2.5.1 Physicochemical Properties  
For a compound to be an effective and efficient drug, it should have a good ADME profile. ADME is 
the acronym for the Absorption, Distribution, Metabolism and Excretion of a drug within an 
organism.24 Therefore, in the design and development of potential therapeutic agents, these 
physicochemical parameters are essential. A few of these properties were determined through a 
combination of in silico and experimental tools. Kerns and Di report that if a compound has a 
solubility of: 
 <10 μg/mL, low solubility 
 10 – 60 μg/mL, moderate solubility 
 >60 μg/mL, high solubility24 
In general, solubility and permeability tend to be complementary to each other up to a point. 
However, if the solubility is too high then the permeability maybe too low; therefore a balance is 
needed to give the best possible absorption. The incorporation of halogens onto the structure of the 
hybrids was envisaged to increase lipophilicity, which may improve penetration through 
membranes. However, this may also lead to a decrease in solubility.  
 
From the results, it was observed that the hybrids had intermediate turbidimetric aqueous solubility 
with most compounds having moderate solubility. In Table 2.6, it was observed that hybrids with 
halogens as substituents had low to moderate solubility due to their lipophilic nature. The 
distribution coefficient (CLogD) was calculated, which is the measure of the distribution of a 
compound between two solvents of different polarities such as octanol and an aqueous buffer 
solution and is thus pH dependent. CLogD values were calculated at the physiological pH of 7.4. The 
lower the CLogD, the greater the aqueous solubility; this was the general trend observed for the 
aminoquinoline-chromone hybrids with the notable exceptions of SN75 and SN76. Also reported are 
the predicted Caco-2 values, which can be used as an indication of permeability. There are several 
different models to determine permeability. However, due to the high cost and technical 
complexities associated with these experiments, the values may be predicted using in silico 
prediction tools. This was the approach used in this study, where the Caco-2 values were predicted 
using Volsurf+. The program reports the Caco-2 values between -1 and +1, with -1 indicating low 
permeability and +1 indicating high permeability.  
Hybrids with moderate to low solubility displayed high permeability as they are more hydrophobic, 
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Series 3 had high ClogD and low Caco-2 values suggesting that the amide linker attached at position 
2 of the chromone imparted greater permeability and poorer solubility compared to the other 
series. Series 2 displayed similar but lower CLogD values as series 3, however, the general trend is 

















Table 2.6: Physicochemical Properties of Hybrid Compounds  
 





























H SN31 30 1.99 3.76 0.78 SN44 16 2.47 3.96 0.73 SN74 8 2.51 3.97 0.57 
Cl SN24 17 2.61 4.52 0.83 SN48 9 3.08 4.71 0.76 SN75 34 3.12 4.73 0.65 
Br SN25 18 2.77 4.73 0.83 SN54 9 3.24 4.93 0.76 SN76 47 3.28 4.94 0.66 
F SN26 16 2.16 3.97 0.65 SN55 41 2.61 4.18 0.56 SN77 4 2.65 4.18 0.43 
OCH3 SN27 4 2.51 3.84 0.73 SN56 8 2.31 4.03 0.65 SN78 2 2.35 4.05 0.50 
CH3 SN28 32 1.99 4.22 0.85 SN57 16 2.47 4.42 0.76  
 
a
 Experimental determined solubility at pH 7.4, 0.01M phosphate buffered saline containing 1 % DMSO 
b
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2.5.2 Biological Evaluation  
In vitro Antiplasmodial Activity 
The in vitro antiplasmodial activities of the synthesized compounds were determined against 
chloroquine-sensitive (CQS) D10 and NF54 strains and the chloroquine-resistant (CQR) K1 strain of  
P. falciparum. Results are summarized in Table 2.7. Chloroquine was used as a control for all 
antiplasmodial assays, where the IC50 (the half maximal inhibitory concentration) of the synthesized 
compounds were determined.   
 
From the results, it was noted that the alkyl-linked hybrids, Series 1, had low potency against the 
D10 strain relative to chloroquine (IC50 = 38.1 nM), with the exception of SN24 (IC50 = 30.7 nM) and 
SN08 (IC50 = 39.8 nM), which were comparable to chloroquine. SN24, the most active hybrid of this 
series, displayed moderate solubility (17 μg/mL) with a high predicted Caco-2 value of 0.83, 
indicating good permeability. Against the NF54 strain, all compounds displayed comparable activity. 
In the K1 strain, the hybrid compounds showed weaker activity relative to their activity in the D10 
and NF54 strains. This suggests some degree of potential cross-resistance with chloroquine. 
Interestingly, the 1:1 molar ratio mixture of the starting materials (D10: IC50 = 32.9 nM; NF54: IC50 = 
29.3 nM) showed comparable potency to chloroquine (IC50 = 38.1 nM) against the CQS strains of P. 
falciparum.  
 
The compounds in Series 2 displayed good potency against the D10 strain when compared to 
chloroquine (IC50 = 38.1 nM), in particular SN48 (IC50 = 20.9 nM), SN54 (IC50 = 46.8 nM) and SN57 
(IC50 = 39.7 nM). Activities against the NF54 strain were also good when compared to chloroquine 
(IC50 = 29.3 nM); hybrids SN44 (IC50 = 38.1 nM), SN54 (IC50 = 57.5 nM) and SN57 (IC50 = 63.3 nM) 
displayed the most potent activity. In the K1 strain, hybrid SN44 (IC50 = 160.0 nM) exhibited the 
highest activity, while the others were less active (IC50 = 160 – 564 nM).  
 
Series 3 contains the hybrids with the aminoquinoline motif attached at position 2 of the chromone 
ring; these compounds showed activity poorer than chloroquine against the D10 and NF54 strains. 
However, in the K1 strain, these compounds displayed better activity than chloroquine  
(IC50 = 190.7 nM). SN77 (IC50 = 37.6 nM) displayed the most potent activity, while SN74  
(IC50 = 82.9 nM) and SN78 (IC50 = 80.9 nM) were slightly less active, but still better than chloroquine. 
These hybrids exhibited low solubility (2 - 47 μg/mL) in general, but relatively moderate predicted 
Caco-2 permeability (0.43 – 0.66). It was observed that the 1:1 molar ratio mixtures of the 
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there may be no added benefit in covalently joining them together. Furthermore, the parent 
compound SN08 (D10: IC50 = 39.8 nM; NF54: IC50 = 33.1 nM), which contains the 4-aminoquinoline 
motif, displayed comparable activity to chloroquine; whereas the chromone precursors displayed 
IC50 values in the micromolar range (6 – 28 μM). This suggests that all the activity is primarily derived 
from the 4-aminoquinoline scaffold of SN08 and not from the chromone substructure. This may 
explain the greater activity observed for the 1:1 molar ratio mixtures. From the data obtained so far, 
it is evident that there are no synergistic effects for the 1:1 molar ratio mixtures. Similarly, 
hybridization of SN08 did not have an antagonistic effect on the antiplasmodial activity. 
 
From the antiplasmodial data obtained, there did not appear to be a significant difference in activity 
between the hybrids with alkyl and amide linkers at position 3 of the chromone ring. Alternatively, 
attachment of the amide linker at position 2 of the chromone ring appeared to significantly improve 
the antiplasmodial activity of the hybrids against the K1 strain of P. falciparum. Additionally, it was 

















Table 2.7: In vitro Antiplasmodial IC50 values against CQS D10 and NF54 strains and CQR, K1 strain of P. falciparum of hybrid compounds 
 
 Series 1 Series 2 Series 3 
R Code 
D10 NF54 K1 
Code 
D10 NF54 K1 
Code 
D10 NF54 K1 
ng/mL      nM ng/mL       nM ng/mL    nM ng/mL      nM ng/mL       nM ng/mL    nM ng/mL      nM ng/mL       nM ng/mL    nM 
H SN31 31.9 84.0 25.2 66.3 75.8 199.6 SN44 27.8 70.6 15.0 38.1 62.9 160.0 SN74 28.6 72.6 35.4 90.0 32.6 82.9 
Cl SN24 12.7 30.7 24.5 59.1 86.0 207.6 SN48 8.95 20.9 28.5 66.5 79.6 185.9 SN75 64.5 150.6 124 289.5  - 
Br SN25 32.4 70.6 36.6 79.8 - - SN54 22.1 46.8 27.2 57.5 - - SN76 143.1 302.7 250 528.9  - 
F SN26 21.8 54.8 21.7 54.5 53.4 134.2 SN55 37.9 92 34.5 83.8 - - SN77 23.2 56.3 37.7 91.5 15.5 37.6 
OCH3 SN27 38.3 - 28.9 70.5 114 278.1 SN56 33.2 78.3 20.2 47.7 239 563.9 SN78 22.39 52.8 36.4 85.9 34.3 80.9 
CH3 SN28 41.0 104 23.7 60.2 69.5 176.5 SN57 16.2 39.7 25.8 63.3 112 274.6     
 SN19 12610 6045 - - - - SN29 29420 13098 - -  - SN69 63810 28410  - - - 













10.3 23.1 14.3 32.0 - - 
 CQ 12.2 38.1 10.6 33.1 61 190.7               
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In vitro Antitumour Activity 
The in vitro antitumour activities of the synthesized compounds were determined against the 
oesophageal cancer WHCO1 cell line. The IC50 values are reported in Table 2.8, where doxorubicin 
was used as a positive control. The results indicate that all compounds in Series 1 had moderate 
antitumour activity, with much higher IC50 values ranging from 13.6 – 23.9 μM, compared to the 
control doxorubicin (IC50 = 0.5 μM). A similar activity trend was observed in the amide-linked hybrids 
(Series 2), except for SN56 (IC50 = 7.6 μM) which displayed moderate antitumour activity. In Series 3, 
all compounds exhibited weaker potency, with the noticeable exception of SN78 (IC50 = 1.78 μM).  
Also noted is the low turbidimetric solubility, moderate CLogD values and intermediate Caco-2 
permeability. Unlike the case in the antiplasmodial activity data, the 1:1 molar ratio mixtures did not 
display superior activity relative to the hybrid compounds. Additionally, the individual monomeric 
precursor compounds also possessed weak antitumour activity. However, it appears that SN08, one 
of the parent compounds, was more potent than its chromone partner in each of the series. This 
could be a reason for the greater activity of the 1:1 molar ratio mixtures.          
Table 2.8: In vitro Antitumour IC50 values of target hybrid compounds against WHCO1 cancer cell line 
 
 
   
 Series 1 Series 2 Series 3 
R Code IC50 (μM) Code IC50 (μM) Code IC50 (μM) 
H SN31 16.7 SN44 11.2 SN74 17.6 
Cl SN24 14.6 SN48 13.0 SN75 14.3 
Br SN25 17.9 SN54 15.4 SN76 52.5 
F SN26 15.4 SN55 18.8 SN77 17.3 
OCH
3 SN27 23.9 SN56 7.6 SN78 1.78 
CH









 SN08:SN19 14.5 SN08:SN29 15.8 SN08:SN69 13.09 
 
SN08 
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In vitro Antimycobacterial Activity 
The target hybrids were also evaluated for their antimycobacterial activity in vitro against the H37Rv 
strain of Mycobacterium tuberculosis using kanamycin as the control. These results are summarized 
in Table 2.9. The alkyl- and amide-linked hybrid molecules, their monomeric parent constituents and 
their 1:1 molar ratio mixtures all displayed very poor antimycobacterial activity with MIC90 at Day 14 
of the assay exceeding 160 μM. MIC90 values are the concentration effecting a 90 %reduction in 
growth at the end of the incubation period relative to untreated controls.27 Only one hybrid, SN78 
(MIC90 = 40 μM), showed moderate antimycobacterial activity. 
 




   
 Series 1 Series 2 Series 3 
R Code MIC90 (μM) Code MIC90 (μM) Code MIC90 (μM) 
H SN31 > 160 SN44 > 160 SN74 > 160 
Cl SN24 > 160 SN48 > 160 SN75 > 160 
Br SN25 > 160 SN54 > 160 SN76 > 160 
F SN26 > 160 SN55 > 160 SN77 > 160 
OCH
3 SN27 > 160 SN56 > 160 SN78 40 
CH





































A series of novel chromone-based hybrids were synthesized and characterized using various 
spectroscopic and analytical techniques, including 1H, 13C NMR, IR spectroscopy and mass 
spectrometry. Some physicochemical properties were determined for the hybrids to help interpret 
their biological activity. The antiplasmodial, antitumour and antimycobacterial activities of the 
hybrids were evaluated in vitro. These compounds exhibited good to excellent antiplasmodial 
activity in both CQS and CQR strains of P. falciparum, and moderate antitumour activity, except 
SN78 (IC50 = 1.78 μM) which demonstrated the most promising activity. From these results it can be 
concluded that the type of linker did not appear to affect pharmacological activity, whereas 
attachment of the amide linker at position 2 of the chromone ring appeared to significantly improve 
the antiplasmodial activity of the hybrids in the CQR K1 strain of P. falciparum. From their poor 
antimycobacterial activity, it was evident that the hybrids do not merit further investigation as 
antimycobacterial agents. 
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Chapter Three – Design, Synthesis and Biological Evaluation of Chromone Analogues 
3.1 Introduction   
This chapter focuses on the design, synthesis and characterization of a series of chromone ester 
derivatives. All target compounds herein discussed were evaluated for their antiplasmodial activities 
against CQS strains of P. falciparum as well as their antimycobacterial activity. The antimalarial 
activity of the 4-aminoquinoline nucleus has been well documented and thus will not be reviewed 
again.1, 2 There is very little known about the antiplasmodial activity of chromones; these small 
molecules have the potential to be developed into drug leads due to their privileged substructure 
classification. In this chapter, chromones will be examined in two ways: a) evaluation of 
antiplasmodial activity by investigation of the structural attributes of the chromone ring and b) 
evaluation of aqueous solubility. 
3.2 Mitochondrial Cytochrome bc1 Complex 
Due to the emergence of resistance to CQ-based therapies, which target the acidic food vacuole in 
the parasite, new antimalarial agents that have different sites and mechanisms of action are needed. 
One such target is the respiratory chain of P. falciparum, which differs from the analogous 
mammalian system.3–5 The Plasmodium cytochrome bc1 complex (ubiquinol:ferricytochrome c 
oxidoreductase) or Complex III in the oxidative phosphorylation chain is the central enzyme in the 
mitochondrial electron transfer chain. Therefore interference of its function results in loss of 
mitochondrial function.6 It is comprised of three catalytic subunits: cytochrome b, which carries a 
low and high potential haeme group, cytochrome c1, which has one covalently bound haeme moiety 
and a high potential Rieske iron-sulfur protein (ISP) containing a [Fe2S2] cluster.  
 
The general function of the complex is to transfer electrons from ubiquinol to cytochrome c coupled 
with the translocation of protons across the inner mitochondrial membrane. This movement of 
electrons creates a proton-motive force (PMF) in the form of an electrochemical proton potential 
that is used in the synthesis of ATP.7, 8 The main feature of this model is the presence of two 
separate ubiquinol:ubiquinone binding sites. The ubiquinol oxidation site (Qo) is located near the 
inner mitochondrial membrane, with the ubiquinone reduction site (Qi) situated at the 
mitochondrial matrix; both the quinol oxidase and quinine reductase are positioned in the 
cytochrome b subunit of the complex.9 The PMF is generated in a bifurcated redox reaction when it 
uses one of the protons released during the oxidation of ubiquinol to reduce the iron-sulfur cluster 
of the Rieske protein. The reduced ISP then undergoes conformational change, bringing the 
cytoplasmic domain of ISP and the haeme of  cytochrome c in contact, thus facilitating electron 
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collapsing the trans-membrane electron potential.10, 11 This inhibits dihydroorotate dehydrogenase 
(DHODH), an enzyme used in the biosynthesis of pyrimidine.5 The malaria parasite is unable to 
salvage pyrimidines, which are a class of heterocycles used in DNA and RNA synthesis, and thus the 
enzyme is essential for its development.12      
 
The Qo and Qi sites in the bc1 subunit have natural inhibitors such as antimycin, myxothiazol and 
stigmatellin (Fig. 3.1).6, 13 Stigmatellin contains a 5,7-dimethoxy-8-hydroxychromone system with a 
hydrophobic alkenyl chain at position 2 and is a potent inhibitor of the Qo site.9 Evidence from 
crystallography, spectroscopy and kinetic studies suggests that stigmatellin binds to the Qo site in a 
distal position and associates with ISP via a hydrogen bond to a histidine residue. This association 
raises the potential of the iron-sulfur cluster and restricts movement of the cytoplasmic domain of 
the ISP and thus inhibits electron transfer, by increasing the redox midpoint of the ISP from 290 mV 
to 540 mV.9, 14 This indicates that the binding of stigmatellin does inhibit the cytochrome bc1 complex 
and thus reduces the function of the mitochrondrion. Stigmatellin was found to be highly toxic in 
humans and is therefore not recommended for medicinal use.6 
 
 
Fig. 3.1: Chemical structures of selected natural inhibitors of the cytochrome bc1 complex 
3.3 Rationale for the Synthesis of Chromone Ethyl Ester Derivatives 
The Qo site can be blocked by inhibitors binding to the quinol active site; various crystallographic 
and spectroscopic analyses indicate that inhibitors of the Qo site can either fix the hydrophilic 
domain of the Rieske iron-sulfur protein or promote movement of the cytoplasmic domain.15 
Molecules that contain a chromone or quinone substructure are postulated to fix the position of the 
hydrophilic domain of the Rieske iron-sulfur protein.16 Currently, atovaquone, a quinone-containing 
structure, is an ubiquinone competitive inhibitor, which inhibits the cytochromone bc1 complex by 
blocking the translocation of electrons. Atovaquone is used in combination with proguanil for the 
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GlaxoSmithKline (Fig. 3.2).17 This is an expensive treatment regimen as the drug has to be taken 
every day for prophylaxis, and since malaria mainly affects the poorer regions of the world, 
alternative cheaper antimalarial agents are needed.     
 
Fig. 3.2: Chemical structures of atovaquone and proguanil, the active agents of the  
antimalarial drug Malarone® 
In the design of potential cytochrome bc1 complex inhibitors, the inclusion of a polar group may 
allow for a hydrogen bond between it and a histidine residue in the Qo active site; these must be 
linked to an alkyl or aryl chain that lies along the cylindrical hydrophobic domain. The investigation 
of an inhibitor with a chromone moiety is justified as it will provide a polar head group with its 
carbonyl at positions C3 and C4 of the chromone ring. Since the chromone substructure is classified as 
a privileged structure, these inhibitors may have the ability to produce compounds with drug-like 
properties.18 Studies on the quinolone template indicate that the incorporation of an aromatic group 
and an ethyl ester chain has the potential to provide drug hits.16 A broad range of aryl groups were 
chosen based on the nature of the groups attached to the ring, i.e. electron-withdrawing groups or 
electron-donating groups. Fig. 3.3 summarizes this concept and illustrating an assortment of aryl 
groups that were used. 
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3.4 Introduction of Aryl Groups onto the Chromone Ring 
In the design of this series, the Suzuki-Miyaura coupling reaction was chosen as the desired route to 
introduce various aryl groups onto position 6 of the chromone ring. This methodology provides easy 
access to diverse chromone derivatives by the introduction of various substituents using palladium-
mediated C-C coupling reactions. 
Overview of Palladium Catalyzed Reactions  
Palladium is the most frequently used transition metal in organic chemistry reactions. There are 
several well-known palladium catalyzed coupling reactions, such as the Buchwald-Hartwig, Heck, 
Negishi, Sonogashira, Stille and Suzuki cross coupling reactions.19 The Nobel Prize in chemistry in 
2010 was awarded to Richard. F. Heck, Ei-ichi Negishi and Akira Suzuki for the development of these 
reactions.20-22 The general mechanism of these types of reactions consist of three steps; oxidative 
addition, transmetallation and reductive elimination (Fig. 3.4). These catalytic cycles generally 
require a zerovalent palladium catalyst. However, Pd(II) complexes are more frequently used as pre-
catalysts as they are more air-stable than the Pd(0) counterparts. If these are used as the pre-
catalysts, they need to be reduced in situ before the cycle can commence. The first step in the 
reaction is oxidative addition, where the Pd(0) inserts between the sp2 carbon and the leaving group 
(LG), like a halogen or triflate, resulting in cleavage of the bond with an increase in oxidation state 
and coordination number of the metal. In terms of reactivity, the reaction is dependent on the 
nature of the LG, such that LG = I>Br≈OTf>>Cl>>F. Transmetallation with a nucleophilic 
organometallic reagent like a boronic acid transfers the R group to the metal and displaces the 
leaving group under basic conditions. Subsequent reductive elimination creates a new carbon-
carbon bond and reduces the oxidation state and coordination number of the metal, thereby 
regenerating the catalyst.23–25 
 
Fig. 3.4: General catalytic cycle for the palladium-mediated cross coupling reactions,  
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Synthesis of Chromone Ester Derivatives 
Various boronic acids with aryl substituents were chosen based on their ring activating and ring 
deactivating properties. 6-Bromo-4-oxo-4H-chromene-3-carbaldehyde, SN20, and 4-chlorophenyl-
boronic acid were used in a pilot reaction, in the determination of viable reaction conditions for the 
introduction of aryl groups at position 6 of the chromone ring. Pd(PPh3)2Cl2 was used as the catalyst, 
1M K2CO3 as the base and DMF as the solvent. This combination previously produced successful 
results within our research group. However, the reaction did not generate the desired product after 
heating at 95 oC overnight (Table 3.1). The reaction was repeated with another high boiling point 
solvent such as 1,4-dioxane with no noticeable effect. Other Suzuki protocols were employed, such 
as changing the base to 1M Na2CO3 and increasing the reaction time; all of these proved futile as the 
desired product was not obtained. It was reasoned that the chromone-3-carbaldehyde was too 
reactive causing the chromone ring to open. To counteract this, the reaction temperature was 
reduced to 60 oC with no improvement. Using standard esterification conditions, SN65 was prepared 
from oxalyl chloride and methanol in anhydrous DCM under anhydrous conditions. Further attempts 
at Suzuki coupling were made using the methyl ester at 60 and 95 oC; this also failed to give the 
desired result. Another strategy employed was to use the base in its solid form to eliminate the 
possibility of water acting as a nucleophile to open the chromone ring; this strategy, too, did not 
yield the desired result.  
 
Table 3.1: Summary of unsuccessful Suzuki cross coupling conditions for the introduction of aryl groups at 




R Base Solvent Temp (oC) Time 
CHO K2CO3 (1M) DMF 95 12 h 
CHO K2CO3 (1M) Dioxane 95 12 h 
CHO Na2CO3 (1M) DMF 95 12 h 
CHO K2CO3 (1M) DMF RT - 60 3 days 
COOCH3 K2CO3 (1M) DMF 95 12 h 
COOCH3 K2CO3 (1M) DMF RT - 60 12 h 
CHO K2CO3 (s) DMF 95 12 h 
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Finally, the product was obtained by using the methodology reported in Shim et al.,26 in which the 
palladium-mediated cross coupling was conducted on 1-(5-bromo-2-hydroxyphenyl)ethanone first 
using standard Suzuki cross coupling reaction conditions to give position 6-substituted aryl 
acetophenones, SN83 – SN92. This was followed by ring closure using a Vilsmeier-Haack reaction as 
described in 2.4.1.1, to give the desired C6-aryl substituted chromone-3-carbaldehyde (Scheme 3.1). 
 
 
Scheme 3.1: Reagents and conditions: i. R-B(OH)2 (1.2 eq), Pd(PPh3)2Cl2 (0.05 eq), 1M K2CO3 (1.05 eq),  
DMF, 95
o




Evidence of an example of a successful Suzuki reaction can be seen in the 1H NMR of SN90 (Fig. 3.5), 
as the protons on the newly introduced ring appear as a multiplet between 7.33 – 7.36 ppm, with H4 
resonating as a doublet with a coupling constant of 2.3 Hz, indicative of long range coupling to H3.  
H3 exists as a doublet of doublet due to its coupling with H2 and H4. Another key feature was the 
singlet upfield in the spectrum, belonging to the methyl protons adjacent to the ketone functional 
group and the presence of the hydroxyl group signal. Evidence for the synthesis of the chromone 
aldehyde was observed in the 1H NMR spectrum of SN90-1. The splitting pattern was similar to that 
observed in the chromone derivatives described in chapter two. Additionally, the hydroxyl signal as 
well as the methyl protons at 2.64 ppm in (a) have disappeared, indicating ring closure. In spectrum 
(b), there is a signal in the aldehyde region, suggesting that the Vilsmeier-Haack reaction proceeded 
successfully. The appearance of the new signal at 8.56 ppm in (b) integrating for one proton was 
assigned to the newly formed chromone proton H1. The signal for H2 has shifted downfield due to 



















H NMR spectra of (a) SN90 and (b) SN90-1 in CDCl3 at 400 MHz 
 
This synthetic procedure was used for the introduction of other functionalized aryl groups to 
produce the chromone aldehydes, SN83-1 – SN92-1.  The aldehydes were subjected to a Lindgren 
oxidation using sodium chlorite and sulfamic acid to produce the chromone-3-carboxylic acids,  
SN83-2 – SN95-2, with aryl groups at C6 of the ring. The chemistry of a Lindgren oxidation was 
extensively discussed in section 2.4.2.1 and will not be repeated here. In the preparation of the ethyl 
chromone esters, it was thought that similar reagents and reaction conditions could be utilized as for 
the synthesis of the methyl esters. A pilot experiment was carried out using SN38 as the source of 
the acid, oxalyl chloride as the chlorinating agent and ethanol as both the reagent and the solvent. 
This reaction was unsuccessful as no conversion to the product was observed; this was deduced by 
TLC analysis of the reaction. Thionyl chloride was then used as an alternative reagent for the 
generation of the acid chloride. The chromone-3-carboxylic acids underwent esterification using 
thionyl chloride and an excess of absolute ethanol under anhydrous conditions at 40 oC overnight 
(Scheme 3.2), to produce the ethyl esters SN38-3 and SN83-3 – SN95-3. Compound SN70-3, a 
chromone ethyl ester with the ester group attached at position 2, was synthesized for comparison 





















Chapter Three – Design, Synthesis and Biological Evaluation of Chromone Analogues  
59 
 
thionyl chloride from the reaction. The pure target compounds either precipitated out of solution or 
were obtained using preparative TLC. 
 
Scheme 3.2: Reagents and conditions: i. SOCl2 (1.5 eq), EtOH, 40 
o
C, 18 h 
 
The mechanism (Fig. 3.6) involves an in situ generated acyl chloride reacting with ethanol in a 
nucleophilic substitution reaction. Thionyl chloride (SOCl2) is used to convert the OH group, a poor 
leaving group, into a good one, by protonating the OH group. SOCl2 contains an electrophilic sulfur in 
its structure and is thus attacked by the nucleophilic oxygen in the carboxylic acid to produce an 
unstable electrophilic intermediate. The Cl- generated reacts with the thio-intermediate to produce 
the acyl chloride releasing HCl and SO2 as gases. The acyl chloride subsequently reacts with the 
alcohol to form an unstable alkoxide intermediate, eliminating the chloride and thus generating the 
ester.24 A summary of the analytical properties of these compounds is presented in Table 3.2. 
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Table 3.2: A summary of the analytical properties of chromone-ethyl ester derivatives, with aryl groups at 





 [M]+ Melting 
Point (oC) Expected     Found 
SN38-3 Br 38 295.9 295.8 85 – 89 
SN83-3 
 
49 372.1 371.8 158 – 162 
SN84-3 
 
83 362.1 362.1 109 – 111 
SN85-3 
 
24 363.1 363.0 141 – 143 
SN87-3 
 
85 300.1 300.0 54 – 56 
SN90-3 
 
78 328.1 328.0 128 – 131 
SN91-3 
 
48 386.2 385.9 31 – 34 
SN92-3 
 
69 324.1 323.9 42 – 45 
 
 
Characterization of Chromone Ester Derivatives 
The 1H and 13C NMR spectra of SN83-3 are presented in Fig. 3.7, illustrating the general pattern of 
the chromone ethyl ester series. The ethyl protons are easily distinguished in the 1H NMR spectrum 
as a triplet and quartet upfield in the spectrum for H11 and H10, respectively. The protons on the 
chromone ring resonate in similar chemical shift regions as those in its precursor, SN83-2  
(6-(4-(methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylic acid), with the exception of H1,  
which has moved upfield in the spectrum due to the less electron-withdrawing ethyl ester group. 
Two sets of doublet of doublets were observed for the aromatic protons on the side chain (H5 – H8), 
which is characteristic of a para-substituted aromatic ring. Analysis of the 13C NMR of the same 
compound further indicated successful synthesis of target compounds as there are two new signals 
upfield in the spectrum, which were assigned as the ethyl chain carbons. The signal at  
173.2 ppm was produced by the carbon of the carbonyl group within the chromone ring, with the 
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indicated that these ethyl esters with aryl groups at position 6 of the heterocyclic ring were 
successfully synthesized.  
 
 
 Fig. 3.7: 
1
H (a) and 
13
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3.5 Improvement of Aqueous Solubility by Disruption of the Molecular Planarity 
In the design of potential therapeutic agents, it is essential to look at all factors that affect the 
absorption of the drug. Solubility, molecular size, particle size, degree of ionization, concentration, 
dosage forms and formulation are just a few that affect the absorption. Thus the aqueous solubility 
of the synthesized compounds is vital.27 For small drug-like molecules, solubility depends on their 
polarity. For example, a compound with a large polar surface area is likely to exhibit greater aqueous 
solubility and therefore the introduction of polar hydrophilic groups by synthetic methods is 
traditionally used to improve solubility.28, 29 A recent review by Ishikawa and colleagues has 
suggested that aqueous solubility may be improved by increasing the dihedral angle of bicyclic 
compounds as this will disrupt the molecular planarity, and thus its symmetry, resulting in an 
improvement of aqueous solubility.30 Ishikawa and co-workers used the rationale that reducing the 
melting point of a crystal will improve the solubility. Melting point is dependent on the crystal lattice 
and crystal packing energies. Therefore, disturbing the crystal packing is another strategy for 
improving solubility. However, literature suggests that predicting the melting point and crystal 
packing of solids is extremely difficult.31, 32  
There are a few examples of improving solubility by chemical modifications, such as removal of the 
aromaticity, an introduction of substituents on the benzylic position, the twisting of fused aromatic 
rings or the disruption of molecular symmetry.30, 27 By attaching aryl substituents onto specific 
positions of the chromone ring, a rotatable biaryl motif is introduced that could potentially disrupt 
the planar symmetry, leading to a lowering of the crystal lattice and crystal packing energies. A 
reduction of these values may lower the melting point and improve its aqueous solubility.  
3.5.1 Effect of the Aryl Group Position on the Chromone Ring  
All the chromone derivatives synthesized thus far have substituents at position 6 of the chromone 
ring. Therefore, to determine the effect of the R group position on the chromone ring, derivatives 
were synthesized with aryl groups at positions 5, 7 and 8 of the heteroaromatic ring. Based on 
literature findings, attachment of an aryl group at positions 5 and/or 8 of the aromatic ring may 
increase the dihedral angle and disrupt the planar symmetry, leading to an improvement in 
solubility.30 The 4-(methylsulfonyl)phenyl moiety was chosen as the constant R group from in silico 
analyses, as it was predicted to have low aqueous solubility as indicated in the partial least squares 
(PLS) plot below. The PLS plot gives an indication of a compound’s solubility; compounds that appear 
in the upper right quadrant are predicted to have high solubility those in the lower left quadrant fall 
in the region of low solubility (Fig. 3.8). Generally, the predicted solubility values were higher than 





















Synthesis and Characterization of Biaryl Chromone Derivatives 
The synthetic methodology employed was the same as that used in section 3.3, with  
3-, 4- and 6-bromo-2-hydroxyacetophenone as the initial starting materials as illustrated in  
Scheme 3.3. There was a slight modification in the temperature of the Suzuki cross coupling 
reaction, as it was raised from 95 oC to 100 oC. Following the palladium-mediated cross coupling 
reaction, the chromone ring was formed in a Vilsmeier-Haack reaction and oxidized to produce the 
acid, which underwent esterification with ethanol.   
 
Scheme 3.3: Reagents and conditions: i. R-B(OH)2 (1.2 eq), Pd(PPh3)2Cl2 (0.05 eq), 1M K2CO3 (1.05 eq), DMF, 
100 
o
C, 12 h; ii. POCl3 (6 eq), DMF, N2, 12 h, H2O, 0 
o
C; iii. NaClO2 (6.0 eq), NH2SO3H (8.0 eq), DCM, H2O, RT,  
4 - 6 h; iv. SOCl2 (1.5 eq), EtOH, 40 
o
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Analytical and spectroscopic data indicated successful synthesis of these chromone derivatives. A 
summary of their analytical properties are displayed in Table 3.3. Since these compounds were 
synthesized to potentially improve the solubility of chromones, their kinetic solubility was 
determined turbidimetrically and will be discussed in section 3.6, along with their antiplasmodial and 
antimycobacterial activities. 
Table 3.3: Summary of the isolated yields, molecular ion peaks and melting points of chromone-ethyl ester 







SN93-3 5 83 157 – 160 
SN83-3 6 49 158 – 162 
SN94-3 7 27 179 – 182 
SN95-3 8 35 158 – 161 
 
3.6 Physicochemical Properties and Biological Evaluation 
Table 3.4 summarizes the physicochemical properties and in vitro pharmacological data of the 
chromone-ethyl esters. The distribution coefficients were calculated at pH 7.4. Caco-2 values are 
given between -1 (indication of low permeability) and +1 (indication of high permeability). The 
solubility data was compared to the general assumption that <10 μg/mL indicates low solubility and 
>60 μg/mL indicates high solubility.27  
 
In general, the chromone-ethyl esters were predicted to have moderate to high Caco-2 values and 
relatively high CLogP values. The compounds were evaluated against the CQS NF54 strain of  
P. falciparum and displayed poor antiplasmodial activity even at the highest concentration (1000 
ng/mL) tested. A comparison was made between SN70-3, a chromone-2-carboxylic acid, and SN38-3, 
a chromone-3-carboxylic acid, to determine which position of attachment of the ester group on the 
chromone ring would yield better activity. From the data, attachment of the ethyl ester group at 
position 2 appeared to improve antiplasmodial activity, it was also noted that SN70-3 (solubility:  
6 μg/mL) had a greater aqueous solubility than SN38-3 (solubility: 1 μg/mL). A number of precursors 
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these acids did not possess any antiplasmodial activity at the highest concentration tested. 
Furthermore, the chromone ethyl esters were evaluated for their antimycobacterial activity against 
the H37Rv strain of Mycobacterium tuberculosis. No antimycobacterial activity was observed for the 
chromones as evidenced from their MIC99 values which exceeded 160 μM. An improvement of the 
solubility may improve the biological activity, as most samples were tested as suspensions since 
precipitation occurred.  
From the results in Table 3.4, these chromones exhibited low solubility, indicating that the choice of 
substituents at position 6 of the chromone ring did not appear to improve solubility when compared 
to SN38-3 (solubility: 1 μg/mL), a non-biaryl compound. However, SN93-3 and SN95-3 (solubility:  
60 μg/mL), with aryl substituents at positions 5 and 8 of the chromone ring, did significantly improve 
aqueous solubility when compared to the compounds (SN83-3 and SN94-3 (solubility: 7 μg/mL)) with 
aryl substituents at positions 6 and 7 on the chromone ring. The ortho-substituted chromones, 
SN93-3 and SN95-3, displayed the greatest solubility as expected, as the 4-(methylsulfonyl)phenyl 
group is expected to rotate out of plane as most biaryls systems tend to do.24 All four compounds 
with a 4-(methylsulfonyl)phenyl group had high melting points, and thus a conclusion cannot be 
drawn here on the concept that disruption of planarity may lower the crystal packing energy and 
thus its melting point, resulting in an improvement of its solubility. Further analysis is needed, such 
as a crystal structure; unfortunately, several attempts to grow X-ray grade crystals were 
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Table 3.4: A summary of the physicochemical properties and biological evaluation against the CQS NF54 



















μg/mL      μM 
SN38-3 Br 6 1 2.74 3.05 1.19 10 33.7 >160 
SN84-3 
 
6 2 4.65 4.87 1.11 1 2.76 160 
SN85-3 
 
6 7 3.30 3.72 0.86 1 2.75 >160 
SN87-3 
 
6 6 3.41 3.62 1.13 1 3.33 >160 
SN90-3 
 
6 2 4.48 4.68 1.33 1 3.04 160 
SN91-3 
 
6 2 5.87 5.59 1.27 1 2.59 160 
SN92-3 
 
6 3 3.13 3.84 1.20 1 2.69 >160 
SN93-3 
 
5 60 2.13 2.54 0.83 1 2.69 >160 
SN83-3 
 
6 7 2.13 2.70 0.77 1 2.69 >160 
SN94-3 
 
7 7 2.13 2.70 0.31 1 2.69 160 
SN95-3 
 
8 60 2.13 2.65 0.38 1 2.69 >160 
SN70-3 
 
- 6 2.74 3.93 1.20 1 3.37 >160 
SN38 
 
6 54 3.19 - -  3.72 >160 
SN83-2 
 
6 69 2.55 - -  2.90 >160 
SN90-2 
 
6 - 4.90 - -  3.33 >160 
        CQ  38 nM 
Kanamycin 
 3.13 μM 
a
 Solubility at pH 7.4, 0.01M phosphate buffered saline containing 1% DMSO, 
b
 CLogD values were estimated at 
pH 7.4 using  Marvin Sketch, 
c


















In the evaluation of chromones as potential antiplasmodial agents with drug-like properties, a small 
series of compounds was synthesized. Each target molecule was fully characterized using various 
spectroscopic and analytical techniques, including 1H NMR, 13C NMR and mass spectrometry. The 
effect of aryl substituents on solubility was also studied. It can be concluded that the attachment of 
the aryl group at positions 5 and 8 improved solubility (60 μg/mL) as compared to positions 6 and 7  
(7 μg/mL). The in silico prediction of solubility was generally higher than the experimentally 
determined results. It was evident from the antiplasmodial and antimycobacterial screening results 
that these compounds have poor potency.  
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Chapter Four – Summary and Conclusion 
4.1 General Summary and Conclusion 
Hybrid compounds which contain the chromone substructure and the 4-aminoquinoline nucleus 
joined by an alkyl or amide linker at either position 2 or 3 of the chromone ring were synthesized. 
Standard synthetic protocols were used, such as the reductive amination reaction for the synthesis 
of the alkyl-linked hybrids and the EDC-HOBt coupling reaction for the synthesis of the amide-linked 
hybrids. Successful synthesis was established using various spectroscopic and analytical techniques, 
such as 1H NMR, 13C NMR, IR and mass spectrometry. The compounds were evaluated for their 
antiplasmodial, antitumour and antimycobacterial activities, as well as for their physicochemical 
properties, specifically turbidimetric aqueous solubility at pH 7.4, CLogP, CLogD and Caco-2.  
 
In the alkyl-linked hybrids, SN24 (D10: IC50 = 30.7 nM) displayed the greatest antiplasmodial activity 
from Series 1. Amongst the amide-linked hybrids at position 3 of the chromone ring (Series 2) 
compounds SN44 (NF54: IC50 = 38.1 nM), SN48 (D10: IC50 = 20.9 nM), SN54 (D10: IC50 = 46.8 nM; 
NF54: IC50 = 57.5 nM) and SN57 (D10: IC50 = 39.7 nM; NF54: IC50 = 63.3 nM) are the most active 
against the CQS strains of P. falciparum. On the other hand, attachment of the amide linker at 
position 2 of the chromone ring (Series 3) significantly improved the antiplasmodial activity of the 
hybrids in the CQR K1 strain of P. falciparum, as seen from SN74 (IC50 = 82.9 nM), SN77 (IC50 = 37.6 
nM) and SN78 (IC50 = 80.9 nM). The hybrids displayed moderate antitumour activity throughout, 
with the exception of SN78 (IC50 = 1.78 μM) which demonstrated the most promising result. All 
compounds tested had low to moderate aqueous solubility; improving their aqueous solubility may 
lead to enhanced activity as some samples precipitated out of solution during testing. One of the 
objectives of this project was to evaluate the linker between the pharmacophores. Based on the 
biological activities of the hybrids, it can be concluded that neither linker resulted in compounds 
with enhanced potency in the in vitro testing.  
 
A further aim of this study was to investigate the effect of the aryl substituents on the chromone 
ring in terms of solubility and pharmacological activity. Various aryl groups were attached at position 
6 of the chromone ring via the Suzuki cross-coupling reaction; these compounds displayed low 
solubility with results <10 μg/mL. In addition, one aryl group the (4-(methylsulfonyl)phenyl) group, 
was chosen to investigate the effect of the attachment position by attaching the aryl substituent at 
positions 5, 6, 7 and 8 of the chromone ring. The ortho-substituted chromones,  
SN93-3 (60 μg/mL) and SN95-3 (60 μg/mL), displayed the highest solubility and it is postulated that 
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symmetry. These chromone-ethyl esters exhibited moderate to poor antiplasmodial and 
antimycobacterial activities. 
 
4.2 Future Work 
Further work on the chromone-aminoquinoline hybrids would be to increase the structural diversity 
in order to create more SAR data based on Series 3, the amide linked hybrids at position 2 of the 
chromone ring, as they displayed the greatest potency. Another aspect of this project to further 
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Chapter Five – Experimental Procedures 
5.1 General Remarks 
All reagents and solvents were purchased from commercial sources and used as received. DCM was 
distilled from phosphorous pentoxide prior to use. Reactions were monitored by thin layer 
chromatography (TLC) using Merck F254 aluminium-backed precoated silica gel plates and were 
visualized by ultraviolet light at 254 nm. Nuclear Magnetic Resonance (NMR) spectra were recorded 
on a Varian Unity XR400 MHz (1H at 400 MHz, 13C at 100 MHz), Varian Unity XR300 MHz (1H at 300 
MHz, 13C at 75 MHz) or a Bruker Ultrashield 400 Plus spectrometer (1H at 400 MHz, 13C at 100 MHz). 
Chemical shifts for 1H and 13C NMR shifts were reported using tetramethylsilane (TMS) as the 
internal standard. The format used for recording 13C NMR data is that accepted by most 
international journals (including American Chemical Society journals). In this format, chemical shift 
values are simply listed without specific assignments to carbon atoms. Infrared (IR) absorptions were 
measured on a Perkin-Elmer Spectrum One FT-IR Spectrometer as KBr pellets. Melting points were 
determined using a Reichert-Hung Thermovar Hot Stage Microscope and are uncorrected. Mass 
Spectrometry was recorded on a JEOL GCmatell in Electron Ionisation mode. High Performance 
Liquid Chromatography (HPLC) was done on a Spectroseries binary gradient pump, P200, using an 
AS100 autosampler and a UV100 detector. The HPLC column was a Phenomenex 150 x 4.60 mm, 3 
micron, Luna 3u C18(2) 100 Å column at ambient temperature. The data was processed on Delta 5.0 
software from DataworX, Pty. Ltd. HLPC grade acetonitrile, methanol and Millipore filtered water 
were used as the eluent.    
5.2 Synthesis of Chromone Derivatives  
5.2.1 General Synthetic Procedur  for Suzuki-coupled Chromone Reactions1 
A solution of 5-bromo-2-hydroxyacetophenone (1.0 eq), boronic acid (1.2 eq) and Pd(PPh3)2Cl2  
(0.05 eq) in dry DMF (10 ml) was degassed for 10 minutes, followed by the addition of 1M K2CO3 
(1.05 eq). The reaction mixture was refluxed at 95 oC for 12 hours and cooled to room temperature; 
distilled water (30 mL) was added and extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with brine and dried over anhydrous Na2SO4. The residue was purified by flash 





















Yellow solid (0.26 g, 37 %); M.p.: 141 – 143 oC; Rf (Hex/EtOAc 8:2) 0.15;  
δH (300 MHz, CDCl3) 2.64 (3H, s, H1), 3.02 (3H, s, H9), 7.01 (1H, d, J 8.7 Hz, 
H2), 7.47 – 7.49 (3H, m, H3, H5, H6), 7.95 (1H, d, J 2.3 Hz, H4) 8.02 (2H, m, H7, 
H8), 12.3 (1H, s, H10); δC (100 MHz, CDCl3) 26.6, 44.5, 115.9, 119.4, 119.9, 
128.0 (2C), 129.7 (2C), 130.0, 135.1, 139.1, 145.3, 162.8, 204.2; EI - m/z 289.9 [M]+.  
1-(4-Hydroxy-4'-(trifluoromethyl)biphenyl-3-yl)ethanone (SN84) 
Pale-yellow solid (0.27 g, 41 %); M.p.: 55 – 57 oC; Rf (Hex/EtOAc 9.7:0.3) 0.40; 
δH (300 MHz, CDCl3) 2.72 (3H, s, H1), 7.10 (1H, d, J 8.7 Hz, H2), 7.64 (1H, dd, 
 J 2.1, 8.6 Hz, H3), 7.69 - 7.74 (4H, m, H5 - H8), 7.94 (1H, d, J 2.3 Hz, H4), 12.3 
(1H, s, H9); δC (100 MHz, CDCl3) 26.5, 119.8, 122.8, 125.7, 125.8, 125.9, 126.9, 129.1, 129.4, 130.7, 
135.1, 142.8, 143.4, 162.4, 202.6; EI - m/z 280.1 [M]+. 
1-(2-Hydroxy-5-(6-(trifluoromethyl)pyridin-3-yl)phenyl)ethanone (SN85) 
Pale-yellow solid (0.35 g, 54 %); M.p.: 111 – 113 oC; Rf (Hex/EtOAc 9:1) 0.30; 
δH (300 MHz, CDCl3) 2.73 (3H, s, H1), 7.14 (1H, d, J 8.7 Hz, H2), 7.71 (1H, dd,  
J 2.3, 8.7 Hz H3), 7.74 (1H, d, J 8.2 Hz, H7), 7.95 (1H, d, J 2.3 Hz, H4), 8.02 (1H, 
dd, J 2.3, 8.1 Hz, H6), 8.92 (1H, d, J 2.2 Hz, H5), 12.4 (1H, s, H8); δC (100 MHz, 
CDCl3) 26.5, 119.7, 120.4, 127.2, 129.4, 134.8, 134.9, 135.9, 138.2, 145.5, 147.9, 148.3, 162.9, 205.3; 
EI - m/z 280.9 [M]+. 
1-(4,4'-Dihydroxybiphenyl-3-yl)ethanone (SN86) 
Yellow solid (0.30 g, 56 %); M.p.: 187 – 189 oC; Rf (Hex/EtOAc 7:3) 0.28;  
δH (300 MHz, CDCl3) 2.69 (3H, s, H1), 5.39 (1H, br s, H9), 6.90 (2H, d,  
J 8.7 Hz, H7, H8), 7.05 (1H, d, J 8.6 Hz, H2), 7.42 (2H, d, J 8.7 Hz, H5, H6), 7.64 
(1H, dd, J 2.3, 8.6 Hz, H3), 7.84 (1H, d, J 2.3 Hz, H4), 12.2 (1H, s, H10);  
δC (100 MHz, CDCl3) 26.3, 115.8, 118.6, 127.8, 128.3, 128.7, 129.5, 129.0, 129.9, 132.4, 134.9, 155.6, 
161.3, 203.3; EI - m/z 227.9 [M]+. 
1-(2-Hydroxy-5-(thiophen-3-yl)phenyl)ethanone (SN87) 
Yellow solid (0.26 g, 50 %); M.p.: 80 – 83 oC; Rf (Hex/EtOAc 7:3) 0.40;  
δH (300 MHz, CDCl3) 2.70 (3H, s, H1), 7.02 (1H, d, J 8.7 Hz, H2), 7.33 (1H, dd, J 2.9, 
8.6 Hz, H5), 7.37 (1H, d, J 8.3 Hz, H6), 7.41 (1H, d, J 2.9 Hz, H7), 7.70 (1H, dd, J 2.2, 
8.5 Hz, H3), 7.92 (1H, d, J 2.2 Hz, H4), 12.3 (1H, s, H8); δC (100 MHz, CDCl3) 26.6, 

















Yellow solid (0.32 g, 56 %); M.p.: 79 – 82 oC; Rf (Hex/EtOAc 9:1) 0.50;  
δH (400 MHz, CDCl3) 2.64 (3H, s, H1), 7.02 (1H, d, J 8.7 Hz, H2), 7.33 – 7.36 (4H, 
m, H5 – H8), 7.61 (1H, dd, J 2.3, 8.6 Hz, H3), 7.82 (1H, d, J 2.3 Hz, H4), 12.1 (1H, s, 
H9), δC (100 MHz, CDCl3) 26.7, 119.1, 119.9, 127.9 (2C), 128.9, 129.1 (2C), 131.1, 
133.5, 135.1, 138.6, 162.1, 204.4; EI - m/z 245.9 [M]+. 
1-(4-Hydroxy-3'-phenoxybiphenyl-3-yl)ethanone (SN91) 
Yellow Oil (0.37 g, 52 %); Rf (Hex/EtOAc 9:1) 0.25; δH (400 MHz, CDCl3) 
2.65 (3H, s, H1), 6.91 – 7.42 (10H, m, Ar H, H2), 7.65 (1H, dd, J 2.2, 8.7 Hz, 
H3), 7.87 (1H, d, J 2.2 Hz, H4), 12.2 (1H, s, H5); δC (100 MHz, CDCl3) 26.7, 
117.2, 117.4, 118.9 (2C), 119.8, 121.5, 122.0, 123.5, 129.0, 129.8 (2C), 130.2, 131.6, 135.2, 141.9, 
157.1, 157.9, 162.1, 204.5. 
1-(4-Hydroxy-2'-methoxybiphenyl-3-yl)ethanone (SN92) 
Pale-yellow solid (0.30 g, 57 %); Rf (Hex/EtOAc 9.5:0.5) 0.35; δH (400 MHz, CDCl3) 
2.65 (3H, s, H1), 3.83 (3H, s, H9), 7.03 – 7.07 (3H, m, H2, H6, H8), 7.33 (2H, m, H5, 
H7), 7.67 (1H, dd, J 2.2, 8.6 Hz, H3), 7.90 (1H, d, J 2.2 Hz, H4), 12.3 (1H, s, H10); δC  
(100 MHz, CDCl3) 26.6, 55.6, 111.4, 117.9 (2C), 119.4, 121.0, 128.7, 129.3, 130.4, 131.5, 137.9, 156.5, 
161.4, 204.6; EI - m/z 242.0 [M]+. 
1-(3-Hydroxy-4'-(methylsulfonyl)biphenyl-2-yl)ethanone (SN93) 
White solid (0.18 g, 53 %); M.p.: 127 – 130 oC; Rf (Hex/EtOAc 5:5) 0.43;  
δH (400 MHz, CDCl3) 2.78 (3H, s, H1), 3.05 (3H, s, H9), 6.73 (1H, d, J 7.4 Hz, H2), 7.00 (1H, 
d, J 8.4 Hz, H4), 7.38 (1H, t, J 7.9 Hz, H3), 7.49 (2H, d, J 8.6 Hz, H5, H6), 7.96 (2H, d, 
 J 8.6 Hz, H7, H8), 11.5 (1H, s, H10); δC (100 MHz, CDCl3) 22.1, 44.5, 118.7, 120.9, 122.2, 
127.8 (2C), 129.9 (2C), 134.2, 140.4, 142.3, 147.7, 161.4, 205.9; EI - m/z 290.0 [M]+. 
1-(3-Hydroxy-4'-(methylsulfonyl)biphenyl-4-yl)ethanone (SN94) 
Yellow solid (0.18 g, 41 %); M.p.: 180 – 183 oC; Rf (Hex/EtOAc 6:4) 0.17;  
δH (400 MHz, CDCl3) 2.68 (3H, s, H1), 3.10 (3H, s, H9), 7.15 (1H, dd, J 1.8, 8.3 Hz, 
H3), 7.22 (d, J 1.8 Hz, H2), 7.79 (2H, m, H5, H6), 7.85 (1H, d, J 8.3 Hz, H4), 8.03 (2H, 
m, H7, H8), 12.3 (1H, s, H10); δC (100 MHz, CDCl3) 23.6, 44.4, 118.7, 119.8, 120.5, 


















Orange solid (0.22 g, 33 %); M.p.: 135 – 139 oC; Rf (Hex/EtOAc 6:4) 0.22;  
δH (400 MHz, CDCl3) 2.63 (3H, s, H1), 3.01 (3H, s, H9), 6.96 (1H, t, J 7.8 Hz, H3), 7.48 (1H, 
d, J 7.8 Hz, H2), 7.71 (2H, m, H5, H6), 7.76 (1H, d, J 8.0 Hz, H4), 7.92 (2H, m, H7, H8), 12.9 
(1H, s, H10); δC (100 MHz, CDCl3) 22.6, 44.3, 118.7, 119.7, 126.9 (2C), 129.9 (2C), 130.9, 
136.8, 138.9, 142.4, 159.4, 162.2, 204.6; EI - m/z 289.9 [M]+. 
 
5.2.2 General Synthetic Procedure of Chromone-3-carbaldehyde Derivatives2  
POCl3 (9.0 eq) was added over a period of 20 minutes to a stirred solution of the selected 
hydroxyacetophenone (1.0 eq) and dry DMF (20 mL) under N2, in a liquid nitrogen bath. The 
resulting mixture was allowed to stir overnight at room temperature and poured into ice water  
(25 mL). The resulting precipitate was filtered and washed with distilled water followed by ethanol. 
Recrystallization from acetone afforded the desired aldehyde. 
4-Oxo-4H-chromene-3-carbaldehyde (SN18) 
White solid (2.9 g, 61 %); M.p.: 147 – 150 oC;  Rf (EtOAc) 0.25; δH (400 MHz, 
CDCl3) 7.48 (1H, t, J 7.2 Hz, H4), 7.52 (1H, d, J 8.8 Hz, H2), 7.75 (1H, t, J 7.8 Hz, H3), 
8.26 (1H, d, J 8.5 Hz, H5), 8.52 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 
118.6, 120.4, 125.4, 126.2, 126.6, 134.8, 156.3, 160.6, 175.7, 188.7; EI - m/z  
174.0 [M]+. 
6-Chloro-4-oxo-4H-chromene-3-carbaldehyde (SN19) 
Pale-yellow solid (2.1 g, 89 %); M.p.: 166 – 167 oC; Rf (EtOAc) 0.29; IR vmax  
(KBr) /cm-1 1662, 1696 (2 x C=O); δH (400 MHz, CDCl3) 7.50 (1H, d, J 8.9 Hz, H2), 
7.69 (1H, dd, J 2.6, 8.9 Hz, H3), 8.25 (1H, d, J 2.7 Hz  H4), 8.53 (1H, s, H1), 10.4 
(1H, s, CHO); δC (100 MHz, CDCl3) 119.1, 120.3, 125.7, 126.4, 132.9, 134.9, 
154.5, 160.6, 174.8, 188.1; EI - m/z 207.9 [M]+; HPLC purity: 99 % (tr = 11.2 min). 
6-Bromo-4-oxo-4H-chromene-3-carbaldehyde (SN20) 
Pale-yellow solid (2.1 g, 90 %); M.p.: 158 – 160 oC; Rf (EtOAc) 0.35;  
δH (400 MHz, CDCl3) 7.42 (1H, d, J 8.9 Hz, H2), 7.84 (1H, dd, J 2.4, 8.9 Hz, H3), 
8.25 (1H, d, J 2.3 Hz, H4), 8.53 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 



















Orange solid (1.6 g, 66 %); M.p.: 146 – 149 oC; Rf (EtOAc) 0.28;  
δH (400 MHz, CDCl3) 7.47 (1H, m, H2), 7.56 (1H, dd, J 2.9, 7.8 Hz, H3), 7.93 (1H, d, 
J 3.1 Hz, H4), 8.54 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 119.5, 
120.8, 122.8, 123.0, 152.4, 159.1, 160.6, 161.5, 175.2, 188.2; EI - m/z 192.1 [M]+. 
6-Methoxy-4-oxo-4H-chromene-3-carbaldehyde (SN22) 
Pale-yellow solid (1.4 g, 61 %); M.p.: 145 – 148 oC; Rf (EtOAc) 0.20;   
δH (400 MHz, CDCl3) 3.92 (3H, s, H5), 7.31 (1H, d, J 9.2 Hz, H2), 7.46 (1H, dd,  
J 3.1, 9.2 Hz, H3), 7.64 (1H, d, J 3.1 Hz, H4), 8.52 (1H, s, H1), 10.4 (1H, s, CHO);  
δC (100 MHz, CDCl3) 56.1, 119.8, 124.4, 125.6, 129.9, 131.2, 147.3, 157.9, 160.2, 175.3, 188.7; LRMS 
(EI) m/z 203.9 [M]+. 
6-Methyl-4-oxo-4H-chromene-3-carbaldehyde (SN23) 
Pale-yellow solid (1.7 g, 73 %); M.p.: 156 – 159 oC; Rf (EtOAc) 0.24;  
δH (400 MHz, CDCl3) 2.47 (3H, s, H5), 7.41 (1H, d, J 8.6 Hz, H2), 7.54 (1H, dd,  
J 2.3, 8.6 Hz, H3), 8.06 (1H, d, J 2.2 Hz, H4), 8.50 (1H, s, H1), 10.4 (1H, s, CHO); 
δC (100 MHz, CDCl3) 20.9, 118.3, 120.3, 125.0, 125.6, 135.9, 136.9, 154.5, 160.5, 176.1, 188.7; EI - 
m/z 187.9 [M]+. 
6-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN83-1) 
Off-white solid (0.19 g, 81 %); M.p.: 254 – 256 oC; Rf (EtOAc) 0.63; δH  
(400 MHz, CDCl3) 3.04 (3H, s, H9), 7.60 (1H, d, J 8.2 Hz, H2), 7.86 (2H, d, J 7.4 
Hz, H5, H8), 7.99 (1H, dd, J 2.3, 8.2 Hz, H3), 8.08 (2H, d, J 7.5 Hz, H6, H7), 8.47 
(1H, d, J 2.2 Hz, H4), 8.51 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 
44.4, 119.4, 124.6, 128.0, 128.1, 129.3, 129.8, 137.7, 140.5, 141.1, 144.1, 148.0, 150.7, 156.2, 160.3, 
175.4, 187.9; EI - m/z 327.8 [M]+. 
4-Oxo-6-(4-(trifluoromethyl)phenyl)-4H-chromene-3-carbaldehyde (SN84-1) 
Yellow solid (0.19 g, 51 %); M.p.: 62 – 65 oC; Rf (EtOAc) 0.70; δH (400 MHz, 
CDCl3) 7.65 (1H, d, J 8.7 Hz, H2), 7.79 – 7.73 (4H, m, H5 – H8), 7.99 (1H, dd,  
J 2.4, 8.7 Hz, H3), 8.52 (1H, d, J 2.4 Hz, H4), 8.58 (1H, s, H1), 10.4 (1H, s, CHO);  
δC (100 MHz, CDCl3) 119.5, 120.5, 124.5, 125.7, 125.9, 126.1 (2C), 126.5, 127.6, 133.5, 138.4, 142.2, 



















White solid (0.16 g, 49 %); M.p.: 55 – 57 oC; Rf (EtOAc) 0.32; δH (300 MHz, 
CDCl3) 7.72 (1H, d, J 8.7 Hz, H2), 7.82 (1H, d, J 8.2 Hz, H7), 8.00 (1H, dd,  
J 2.4, 8.7 Hz, H3), 8.14 (1H, dd, J 2.0, 8.0 Hz, H6), 8.53 (1H, d, J 2.4 Hz, H4), 
8.59 (1H, s, H1), 9.01 (1H, d, J 2.1 Hz, H5), 10.4 (1H, s, CHO); δC (100 MHz, 
CDCl3) 119.8, 120.5, 120.6, 124.8, 125.9, 133.2, 134.8, 135.0, 135.6, 137.1, 148.0, 148.3, 156.3, 160.4, 
175.3, 187.8; EI - m/z 318.8 [M]+. 
6-(4-Hydroxyphenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN86-1) 
Brown solid (0.08 g, 30 %); M.p.: 229 – 231 oC; Rf (EtOAc) 0.36; δH (300 MHz, 
CDCl3) 4.85 (1H, br s, H9), 6.87 (2H, d, J 8.7 Hz, H5, H8), 7.48 (2H, d, J 8.7 Hz, H6, 
H7), 7.56 (1H, d, J 8.7 Hz, H2), 7.85 (1H, dd, J 2.3, 8.6 Hz, H3), 8.37 (1H, d,  
J 2.3 Hz, H4), 8.49 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, DMSO-d6) 116.4, 116.5, 118.3, 123.2, 
124.6, 130.8, 130.9, 131.6, 133.8, 135.7, 136.1, 156.3, 157.8, 170.5, 176.3, 189.6; EI - m/z 266.0 [M]+. 
4-Oxo-6-(thiophen-3-yl)-4H-chromene-3-carbaldehyde (SN87-1)    
Brown solid (0.21 g, 56 %); M.p.: 156 – 158 oC; Rf (EtOAc) 0.16; δH (300 MHz, 
CDCl3) 7.45 (2H, m, H2, H5), 7.56 (1H, d, J 8.7 Hz, H6), 7.59 (1H, d, J 2.3 Hz, H7), 
7.96 (1H, dd, J 2.2, 8.7 Hz, H3), 8.46 (1H, d, J 2.2 Hz, H4), 8.53 (1H, s, H1), 10.4 
(1H, s, CHO); δC (100 MHz, CDCl3) 119.1, 120.3, 121.9, 122.9, 125.6, 126.1, 127.1, 132.8, 134.6, 139.9, 
155.2, 160.4, 175.9, 188.5; EI - m/z 254.9 [M]+. 
6-(4-Chlorophenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN90-1) 
Yellow solid (0.25 g, 45 %); M.p.: 169 – 171 oC; Rf (EtOAc 7:3) 0.20;  
δH (400 MHz, CDCl3) 7.46 (1H, d, J 8.7 Hz, H2), 7.59 – 7.62 (4H, m, H5 – H8), 7.93 
(1H, dd, J 2.4, 8.7 Hz, H3), 8.46 (1H, d, J 2.4 Hz, H4), 8.56 (1H, s, H1), 10.4 (1H, s, 
CHO); δC (100 MHz, CDCl3) 119.3, 120.0, 123.9, 125.6, 128.5 (2C), 129.3 (2C), 133.3, 134.6, 137.2, 
138.7, 160.6, 172.3, 175.9, 188.5; EI - m/z 284.0 [M]+. 
4-Oxo-6-(3-phenoxyphenyl)-4H-chromene-3-carboxylic acid (SN91-1) 
Pale-brown solid (0.19 g, 42 %); Rf (DCM) 0.26; δH (400 MHz, CDCl3)  
7.05 – 7.08 (3H, m, Ar H), 7.38 – 7.43 (6H, m, Ar H), 7.59 (1H, d, J 8.7 Hz, 
H2), 7.59 (1H, dd, J 2.4, 8.7 Hz, H3), 8.47 (1H, d, J 2.4 Hz, H4), 8.55 (1H, s, 
H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 117.6, 118.5 (2C), 119.8, 119.2, 120.4, 122.1, 123.6, 


















Yellow solid (0.25 g, 73 %); M.p.: 156 – 158 oC; Rf (EtOAc) 0.16;  
δH (300 MHz, CDCl3) 3.84 (3H, s, H9), 7.05 (2H, m, H6, H8), 7.38 (2H, m, H5, H7), 
7.55 (1H, d, J 8.7 Hz, H2), 7.96 (1H, dd, J 2.2, 8.7 Hz, H3), 8.42 (1H, d, J 2.2 Hz, H4), 
8.55 (1H, s, H1), 10.4 (1H, s, CHO); δC (100 MHz, CDCl3) 55.6, 111.4, 117.9, 120.4, 121.1, 125.1, 126.5, 
128.3, 129.7, 130.8, 136.4, 137.5, 155.2, 156.4, 160.4, 176.1, 188.7; EI - m/z 240.9 [M]+. 
5-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN93-1) 
Pink solid (0.17 g, 83 %), M.p.: 213 – 216 oC; Rf (EtOAc) 0.28; δH (400 MHz, CDCl3) 
3.11 (3H, s, H9), 7.23 (2H, d, J 8.6 Hz, H5, H6), 7.48 (1H, d, J 7.4 Hz, H2), 7.60 (1H, d,  
J 8.5 Hz, H4), 7.75 (1H, t, J 7.9 Hz, H3), 7.97 (2H, d, J 8.6 Hz, H7, H8), 8.49 (1H, s, H1), 
10.2 (1H, s, CHO); δC (100 MHz, CDCl3) 44.6, 119.3, 121.1, 122.5, 126.8 (2C), 129.5 
(2C), 129.7, 133.9, 139.6, 141.8, 146.4, 157.3, 159.9, 175.9, 188.3; EI - m/z 327.9 
[M]+. 
7-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN94-1) 
Brown solid (0.18 g, 46 %); M.p.: 239 – 241 oC; Rf (EtOAc) 0.58; δH (400 MHz, 
CDCl3) 3.06 (3H, s, H9), 7.69 (2H, m, H2, H3), 7.79 (2H, d, J 8.2 Hz, H5, H6), 8.04 
(2H, d, J 8.2 Hz, H7, H8), 8.35 (1H, d, J 8.2 Hz, H4), 8.52 (1H, s, H1), 10.4 (1H, s, 
CHO); δC (100 MHz, CDCl3) 44.5, 117.3, 120.7, 125.7, 127.2, 128.4 (2C), 128.5 
(2C), 141.1, 143.9, 145.8, 156.6, 160.8, 167.6, 175.5, 188.3; EI - m/z 328.0 [M]+. 
8-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde (SN95-1) 
Yellow solid (0.03 g, 25 %); M.p.: 239 – 241 oC; Rf (EtOAc) 0.19; δH (400 MHz, CDCl3) 
3.07 (3H, s, H9), 7.55 (1H, t, J 7.8 Hz, H3), 7.65 – 7.69 (3H, m, H2, H5, H6), 8.08 (2H, d,  
J 8.6 Hz, H7, H8), 8.33 (1H, d, J 7.9 Hz, H4), 8.44 (1H, s, H1), 10.3 (H, s, CHO);  
δC (100 MHz, CDCl3) 44.5, 120.4, 125.9, 126.8, 127.7 (2C), 130.5 (2C), 131.3, 135.7, 
137.2, 140.6, 152.9, 160.2, 175.7, 188.2; EI - m/z 327.9 [M]+. 
5.2.3 General Synthetic Procedure of Chromone-3-carboxylic acid Derivatives3 
An aqueous solution of NH2SO3H (8.0 eq) was added dropwise to a stirred solution of aldehyde  
(1.0 eq) in DCM at 0 oC, followed by the dropwise addition of an aqueous solution of NaClO2 (6.0 eq). 
The resulting suspension was vigorously stirred for 4 – 6 hours at room temperature. The aqueous 
layer was extracted with DCM (3 x 50 mL). The organic layers were combined and washed with brine, 
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4-Oxo-4H-chromene-3-carboxylic acid (SN11) 
White solid (1.7 g, 78 %); M.p.: 147 – 150 oC; Rf (DCM) 0.25; δH (400 MHz, CDCl3) 
7.60 (1H, t, J 8.1 Hz, H4), 7.65 (1H, d, J 8.1 Hz, H2), 7.87 (1H, t, J 8.2 Hz, H3), 8.34 
(1H, d, J, 8.0 Hz, H5), 9.01 (1H, s, H1), 13.4 (1H, s, OH); δC (100 MHz, CDCl3) 113.6, 
119.1, 123.5, 126.6, 127.5, 136.2, 136.9, 157.1, 164.0, 179.6; EI - m/z 190.0 [M]+. 
6-Chloro-4-oxo-4H-chromene-3-carboxylic acid (SN29) 
White solid (0.53 g, 77 %); M.p.: 212 – 215 oC; Rf (DCM) 0.29; IR vmax (KBr) /cm
-1 
1625, 1739 (2 x C=O), 3443 (O-H); δH (400 MHz, CDCl3) 7.87 (1H, d, J 8.9 Hz, H2), 
7.79 (1H, dd, J 2.6, 8.9 Hz, H3), 8.28 (1H, d, J 2.5 Hz, H4), 8.99 (1H, s, H1), 13.3 
(1H, s, OH); δC (100 MHz, CDCl3) 113.6, 120.8, 124.5, 125.9, 133.9, 136.5, 155.3, 163.7, 164.2, 178.6; 
EI - m/z 223.9 [M]+; HPLC purity: 98 % (tr = 9.30 min). 
6-Bromo-4-oxo-4H-chromene-3-carboxylic acid (SN38) 
Pale yellow solid (0.46 g, 56 %); M.p.: 175 – 178 oC; Rf (DCM) 0.16; δH (400 MHz, 
CDCl3) 7.55 (1H, d, J 8.9 Hz, H2), 7.75 (1H, dd, J 2.4, 8.9 Hz, H3), 8.46 (1H, d,  
J 2.4 Hz, H4), 9.01 (1H, s, H1), 13.1 (1H, s, OH); δC (100 MHz, CDCl3) 113.6, 120.9, 
121.3, 124.6, 129.1, 139.3, 155.7, 163.7, 164.3, 178.4; EI - m/z 267.9 [M]+. 
6-Fluoro-4-oxo-4H-chromene-3-carboxylic acid (SN40) 
White solid (0.30 g, 85 %); M.p.: 222 – 224 oC; Rf (DCM) 0.24; δH (400 MHz, 
CDCl3) 7.59 (1H, d, J 9.2 Hz, H2), 7.69 (1H, dd, J 3.0, 9.2 Hz, H3), 7.97 (1H, d,  
J 3.0 Hz, H4), 9.02 (1H, s, H1), 13.1 (1H, s, OH); δC (100 MHz, CDCl3) 110.9, 111.2, 
120.7, 120.8, 123.8, 124.1, 159.1, 161.6, 163.6, 178.3; EI - m/z 208.0 [M]+. 
6-Methoxy-4-oxo-4H-chromene-3-carboxylic acid (SN41) 
Pale-yellow solid (0.53 g, 81 %); M.p.: 155 – 157 oC; Rf (DCM) 0.25; δH (400 MHz, 
CDCl3) 3.94 (3H, s, H5), 7.44 (1H, d, J 9.2 Hz, H2), 7.58 (1H, dd, J 3.1, 9.2 Hz, H3), 
7.63 (1H, d, J 3.1 Hz, H4), 8.99 (1H, s, H1), 13.5 (1H, s, OH); δC (100 MHz, CDCl3) 
55.6, 113.2, 121.3, 125.6, 125.9, 126.3, 149.8, 156.7, 163.5, 164.2, 178.6; EI - 
m/z 220.0 [M]+. 
6-Methyl-4-oxo-4H-chromene-3-carboxylic acid (SN42) 
White solid (0.54 g, 77 %); M.p.: 225 – 228 oC; Rf (DCM) 0.25; δH (400 MHz, CDCl3) 
2.53 (3H, s, H5), 7.46 (1H, d, J 8.6 Hz, H2), 7.62 (1H, dd, J 1.9, 8.6 Hz, H3), 8.11 (1H, 
d, J 2.0 Hz, H4), 8.99 (1H, s, H1), 13.5 (1H, s, OH); δC (100 MHz, CDCl3) 21.4, 113.2, 
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6-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN83-2) 
Yellow solid (0.14 g, 79 %); M.p.: 243 – 246 oC; Rf (DCM/MeOH 9:1) 0.45;  
δH (400 MHz, CDCl3) 3.12 (3H, s, H9), 7.79 (1H, d, J 8.8 Hz, H2), 7.87 (2H, d,  
J 8.2 Hz, H5, H8), 8.07 – 8.10 (3H, m, H3, H6, H7), 8.56 (1H, d, J 2.3 Hz, H4), 9.06 
(1H, s, H1), 13.2 (1H, s, OH); δC (100 MHz, CDCl3) 45.7, 110.5, 119.2, 123.4, 127.8 (2C), 129.5, 129.8, 
131.4, 135.8, 136.2, 140.1, 145.6, 156.2, 164.1, 166.2, 177.6; LRMS (EI) m/z 344.0 [M]+. 
4-Oxo-6-(4-(trifluoromethyl)phenyl)-4H-chromene-3-carboxylic acid (SN84-2) 
Pale-yellow solid (0.04 g, 46 %); Rf (DCM) 0.30; δH (400 MHz, CDCl3) 7.58 (1H, 
d, J 8.6 Hz, H2), 7.77 – 7.80 (4H, m, H5 – H8), 8.10 (1H, d, J 8.6 Hz, H3), 8.53 (1H, 
s, H4), 9.04 (1H, s, H1), 13.2 (1H, s, OH); δC (100 MHz, CDCl3) 113.2, 119.7, 
123.3, 124.3, 126.1 (2C), 126.2, 127.7 (2C), 130.6, 134.8, 139.1, 141.8, 156.3, 163.8, 164.0, 179.2;  
EI - m/z 334.0 [M]+. 
4-Oxo-6-(6-(trifluoromethyl)pyridin-3-yl)-4H-chromene-3-carboxylic acid (SN85-2) 
White solid (0.09 g, 56 %); Rf (DCM) 0.18; δH (400 MHz, CDCl3) 7.84 (2H, m, 
H2, H7), 8.09 (1H, dd, J 2.2, 8.9 Hz, H3), 8.16 (1H, dd, J 2.3, 8.2 Hz, H6), 8.56 
(1H, d, J 2.2 Hz, H4), 9.02 (1H, d, J 2.3 Hz, H5), 9.07 (1H, s, H1), 13.1 (1H, s, 
OH); δC (100 MHz, CDCl3) 118.8, 120.2, 120.7, 124.0, 125.9 (2C), 134.6, 135.1, 135.8, 136.0, 148.5 
(2C), 156.7, 162.5, 164.0, 178.9; EI - m/z 334.9 [M]+. 
6-(4-Hydroxyphenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN86-2) 
Yellow oil (0.03 g, 8 %), Rf (DCM/MeOH 98:2) 0.52; δH (400 MHz, CDCl3) 5.21 
(1H, br s, H9), 6.91 (2H, d, J 8.9 Hz, H6, H8), 7.56 – 7.60 (3H, m, H2, H5, H7), 
8.17 (1H, dd, J 2.3, 8.7 Hz, H3), 8.74 (1H, d, J 2.4 Hz, H4), 9.01 (1H, s, H1), 13.3 
(1H, s, OH); δC (100 MHz, DMSO-d6) 110.8, 116.9 (2C), 119.2, 124.6, 131.3 (2C), 132.4, 133.5, 135.5, 
137.8, 155.8, 157.9, 166.8, 168.3, 179.5; EI - m/z 282.0 [M]+. 
4-Oxo-6-(thiophen-3-yl)-4H-chromene-3-carboxylic acid (SN87-2) 
Pale-yellow solid (0.03 g, 78 %); Rf (DCM) 0.20; δH (400 MHz, CDCl3) 7.41 (2H, m, 
H2, H5), 7.56 (1H, d, J 2.2 Hz, H7), 7.62 (1H, d, J 8.8 Hz H6), 8.03 (1H, dd,  
J 1.3, 8.7 Hz, H3), 8.43 (1H, d, J 1.6 Hz, H4), 8.95 (1H, s, H1), 13.3 (1H, s, OH);  
δC (100 MHz, CDCl3) 119.3, 122.2, 122.8, 123.4, 126.0, 127.4, 132.1, 132.4, 134.1, 137.1, 156.2, 















Chapter Five – Experimental Procedures 
80 
 
6-(4-Chlorophenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN90-2) 
Yellow solid (0.47 g, 34 %); M.p.: 153 – 156 oC; Rf (DCM) 0.30; δH (400 MHz, 
CDCl3) 7.39 (2H, d, J 7.9 Hz, H5, H8), 7.50 (2H, d, J 7.9 Hz, H6, H7), 7.65 (1H, d,  
J 8.7 Hz, H2), 7.97 (1H, dd, J 1.5, 8.7 Hz, H3), 8.38 (1H, d, J 1.6 Hz, H4), 8.95 (1H, 
s, H1), 13.0 (1H, s, OH); δC (100 MHz, CDCl3) 113.1, 119.4, 123.2, 123.8, 128.4, 128.5 (2C), 129.4 (2C), 
134.6, 134.9, 136.7, 139.4, 156.0, 163.8, 179.3; EI - m/z 298.9 [M]+. 
4-Oxo-6-(3-phenoxyphenyl)-4H-chromene-3-carboxylic acid (SN91-2) 
Yellow solid (0.13 g, 65 %); M.p.: 38 – 40 oC; Rf (DCM) 0.28;  
δH (400 MHz, CDCl3) 7.03 – 7.05 (3H, m, Ar H), 7.36 – 7.45 (6H, m, Ar H), 
7.68 (1H, d, J 8.8 Hz, H2), 8.02 (1H, dd, J 2.1, 8.8 Hz, H3), 8.45 (1H, d,  
J 2.1 Hz, H4), 9.00 (1H, s, H1), 13.3 (1H, s, OH); δC (100 MHz, CDCl3) 113.9, 117.6, 118.7, 119.1 (2C), 
120.3, 122.01, 123.2, 123.8, 124.0, 129.9 (2C), 130.6, 134.8, 139.9, 140.2, 156.1, 156.8, 158.2, 163.8, 
164.0, 179.3; LRMS (EI) m/z 358.0 [M]+.  
6-(2-Methoxyphenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN92-2) 
Pale-yellow solid (0.24 g, 92 %); Rf (DCM) 0.35; δH (400 MHz, CDCl3) 3.83 (3H, 
s, H9), 7.07 (2H, m, H6, H8), 7.38 (2H, m, H5, H7), 7.66 (1H, d, J 8.8 Hz, H2), 8.06 
(1H, dd, J 2.2, 8.8 Hz, H3), 8.44 (1H, d, J 2.2 Hz, H4), 9.02 (1H, s, H1), 13.1 (1H, 
s, OH); δC (100 MHz, CDCl3) 55.6, 111.4, 118.1, 121.2, 122.7, 126.3, 129.6, 
130.1, 130.8, 135.2, 137.2, 137.7, 138.3, 155.6, 156.4, 163.7, 179.5; EI - m/z 296.0 [M]+. 
5-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN93-2)  
Yellow solid (0.15 g, 64 %); M.p.: 254 – 256 oC; Rf (DCM) 0.57; δH (400 MHz, CDCl3) 
3.16 (3H, s, H9), 7.35 (1H, d, J 7.4 Hz, H2), 7.49 (2H, d, J 8.6 Hz, H5, H6), 7.73 (1H, d, 
J 8.5 Hz, H4), 7.73 (1H, t, J 7.8 Hz, H3), 8.01 (2H, d, J 8.6 Hz, H7, H8), 9.02 (1H, s, H1), 
13.0 (1H, s, OH); δC (100 MHz, CDCl3) 43.6, 112.7, 118.4, 119.3, 125.9 (2C), 128.5 
(2C), 129.1, 134.0, 138.9, 140.9, 144.7, 156.7, 162.2, 162.7, 178.4; EI - m/z 344.0 
[M]+. 
7-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN94-2) 
Yellow solid (0.06 g, 37 %); M.p.: 256 – 258 oC; Rf (DCM) 0.15;  
δH (400 MHz, CDCl3) 3.07 (3H, s, H9), 7.78 – 7.81 (3H, m, H3, H5, H6), 8.05 (3H, 
m, H2, H7, H8), 8.41 (1H, d, J 8.2 Hz, H4), 9.00 (1H, s, H1), 12.7 (1H, s, OH);  
δC (100 MHz, DMSO-d6) 48.8, 120.1, 122.4, 128.3, 130.9, 131.6, 132.9 (2C), 
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8-(4-(Methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylic acid (SN95-2) 
Orange solid (0.098 g, 38 %); M.p.: 162 – 165 oC; Rf (DCM) 0.34; δH (400 MHz, CDCl3) 
3.08 (3H, s, H9); 7.52 (1H, t, J 7.8 Hz, H3), 7.64 –  7.67 (3H, m, H2, H5, H6), 8.03 (2H, m, 
H7, H8), 8.36 (1H, d, J 8.0 Hz, H4), 8.90 (H, s, H1), 13.0 (1H, s, OH); δC (100 MHz, CDCl3) 
44.5, 119.1, 123.7, 125.9, 126.8, 127.3, 127.9 (2C), 130.5 (2C), 136.8, 137.4, 145.0, 
147.1, 163.5, 175.5, 204.6; EI - m/z 344.1 [M]+. 
5.2.4. General Synthetic Procedure of Chromone-2-carboxylic acid Derivatives4  
A solution of diethyl oxalate (1.1 eq) and the selected hydroxyacetophenone (1.0 eq) was added 
dropwise under N2 to a stirred ethanolic solution of NaOEt (generated in situ by adding Na metal  
(3.2 g, 0.1 mol) to absolute EtOH (18 mL)). The yellow reaction mixture was refluxed at 95 oC for  
2 hours. After cooling, the mixture was added to Et2O (100 mL) and left to stand overnight. The solid 
was filtered, washed with Et2O (50 mL), acidified with 2M HCl (100 mL), and the resulting yellow 
mixture was extracted with Et2O (3 x 100 mL). The combined organic layers were dried over 
anhydrous Na2SO4 and concentrated in vacuo to give a yellow residue. Glacial acetic acid (20 mL) and 
conc. HCl (20 mL) were added to the residue and refluxed at 95 oC for 2 hours. After cooling, the 
resulting precipitate was filtered and washed with acetic acid. Recrystallization from acetic acid 
afforded the carboxylic acids.  
4-Oxo-4H-chromene-2-carboxylic acid (SN68) 
White solid (7.6 g, 72 %); M.p.: 252 – 255 oC; Rf (EtOAc) 0.51; δH (300 MHz,  
DMSO-d6)
* 6.87 (1H, s, H1), 7.49 (1H, t, J 8.1 Hz, H4), 7.68 (1H, d, J 8.2 Hz, H2), 7.83 
(1H, t, J 8.1 Hz, H3); 8.01 (1H, d, J 8.0 Hz, H5); δC (100 MHz, DMSO-d6) 113.7, 
119.0, 123.9, 125.0, 126.2, 135.3, 153.4, 155.6, 161.7, 177.7; EI - m/z 190.0 [M]+. 
6-Chloro-4-oxo-4H-chromene-2-carboxylic acid (SN69) 
Pale grey solid (0.79 g, 60 %); M.p.: 242 – 245 oC; Rf (EtOAc) 0.56;  
IR vmax (KBr) /cm
-1 1634, 1735 (2 x C=O), 3425 (O-H); δH (300 MHz, DMSO-d6)
* 6.93 
(1H, s, H1), 7.79 (1H, d, J 9.1 Hz, H2), 7.90 (1H, dd, J 2.7, 9.0 Hz, H3), 7.98 (1H, d,  
J 2.8 Hz, H4); δC (100 MHz, DMSO-d6) 113.7, 121.8, 124.3, 125.2, 130.9, 135.4, 
153.9, 154.4, 161.5, 176.9; EI - m/z 223.9 [M]+; HPLC purity: 97 % (tr = 8.02 min). 
 
 
                                                          
*
 The carboxylic acid proton was not observed, presumably due to the rapid exchange with water present in 
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6-Bromo-4-oxo-4H-chromene-2-carboxylic acid (SN70) 
Grey solid (1.12 g, 87 %); M.p.: 263 – 265 oC; Rf (EtOAc) 0.52; δH (300 MHz,  
DMSO-d6)
* 6.94 (1H, s, H1), 7.72 (1H, d, J 8.9 Hz, H2), 8.01 (1H, dd, J 2.5, 8.9 Hz, H3), 
8.12 (1H, d, J 2.5 Hz, H4); δC (100 MHz, DMSO-d6) 113.6, 118.6, 121.7, 125.4, 
127.2, 137.9, 153.8, 154.6, 161.3, 176.6; EI - m/z 267.7 [M]+. 
6-Fluoro-4-oxo-4H-chromene-2-carboxylic acid (SN71) 
Grey solid (0.37 g, 28 %); M.p.: 243 – 245 oC; Rf (EtOAc) 0.42; δH (300 MHz,  
DMSO-d6)
* 6.92 (1H, s, H1), 7.74 – 7.79 (3H, m, H2, H3, H4); δC (100 MHz, DMSO-d6) 
110.1, 122.3, 123.9, 125.5, 152.4, 154.0, 158.6, 160.9, 161.8, 177.5; EI - m/z 207.8 
[M]+. 
6-Methoxy-4-oxo-4H-chromene-2-carboxylic acid (SN72) 
Off-white solid (0.80 g, 62 %); M.p.: 279 – 281 oC; Rf (EtOAc) 0.56; δH (300 MHz, 
DMSO-d6)
* 3.88 (3H, s, H5), 6.89 (1H, s, H1), 7.42 (1H, d, J 9.2 Hz, H2), 7.47 (1H, dd, 
J 3.2, 9.2 Hz, H3), 7.70 (1H, d, J 3.1 Hz, H4); δC (100 MHz, DMSO-d6) 55.9, 104.8, 
112.7, 120.6, 124.5, 124.7, 150.3, 153.1, 157.1, 161.6, 177.4; EI - m/z 219.9 [M]+. 
5.2.5 Synthesis of Chromone Esters2 
5.2.5.1 General Synthetic Procedure for Chromone-methyl Esters 
Oxalyl chloride (2.5 eq) was added dropwise to a stirred solution of SN38 (1.0 eq) in dry DCM (20 mL) 
under N2. After 90 minutes, the reaction temperature was lowered to 0 
oC, followed by the dropwise 
addition of anhydrous MeOH (3.5 mL). The reaction mixture was warmed to room temperature and 
stirred overnight. The solvent was removed in vacuo and recrystallization from EtOH afforded the 
product. 
Methyl 4-oxo-4H-chromene-3-carboxylate (SN64) 
White solid (0.05 g, 10 %); M.p.: 74 – 79 oC; Rf (DCM/MeOH 95:5) 0.81;  
δH (300 MHz, CDCl3) 3.93 (3H, s, H6), 7.48 (2H, m, H2, H4), 7.70 (1H, t,  
J 8.6 Hz, H3), 8.28 (1H, d, J 7.9 Hz, H5), 8.68 (1H, s, H1); δC (100 MHz, CDCl3) 52.4, 
116.2, 118.2, 125.2, 126.3, 126.7, 134.2, 138.9, 155.6, 162.0, 173.4; EI - m/z 203.9 [M]+. 
 
 
                                                          
*
 The carboxylic acid proton was not observed, presumably due to the rapid exchange with water present in 
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Methyl 6-bromo-4-oxo-4H-chromene-3-carboxylate (SN65) 
White solid (0.30 g, 48 %); M.p.: 109 – 111 oC; Rf (DCM/MeOH 95:5) 0.60; δH  
(300 MHz, CDCl3) 3.93 (3H, s, H5), 7.40 (1H, d, J 8.9 Hz, H2), 7.79 (1H, dd,  
J 2.5, 8.9 Hz, H3), 8.40 (1H, d, J 2.4 Hz, H4), 8.67 (1H, s, H1); δC (100 MHz, CDCl3) 
52.5, 116.3, 120.1, 126.5, 129.2, 134.5, 137.3, 154.5, 162.1, 163.6, 172.1; EI - m/z 281.8 [M]+. 
5.2.5.2 General Synthetic Procedure for Chromone-ethyl Esters 
Thionyl chloride (1.5 eq) was added dropwise to a solution of the desired carboxylic acid in absolute 
ethanol at 0 oC. The reaction mixture was stirred at 0 oC for 30 minutes, then warmed to 40 oC for  
18 hours. A saturated solution of Na2CO3 was added and the aqueous mixture was extracted with 
EtOAc (3 x 30 mL). The combined organic layers were washed with a saturated solution of Na2CO3, 
dried over Na2SO4 and the solvent removed to afford the products.  
Ethyl 6-bromo-4-oxo-4H-chromene-3-carboxylate (SN38-3) 
Yellow solid (0.06 g, 38 %); M.p.: 85 – 89 oC; Rf (Hex/EtOAc 5:5) 0.58;  
δH (400 MHz, CDCl3) 1.40 (3H, t, J 7.1 Hz, H6), 4.40 (2H, q, J 7.1 Hz, H5), 7.39 
(1H, d, J 8.8 Hz, H2), 7.79 (1H, dd, J 2.3, 8.9 Hz, H3), 8.40 (1H, d, J 2.3 Hz, H4), 
8.65 (1H, s, H1); δC (100 MHz, CDCl3) 14.2, 61.6, 116.6, 119.9, 120.1, 126.5, 129.2, 137.2, 154.5, 
161.7, 162.9, 172.1; EI - m/z 295.8 [M]+; HPLC purity: 97 % (tr = 5.32 min).  
Ethyl 6-bromo-4-oxo-4H-chromene-2-carboxylate (SN70-3) 
Grey solid (0.11 g, 66 %); M.p.: 132 – 134 oC; Rf (Hex/EtOAc 5:5) 0.80;  
δH (400 MHz, CDCl3) 1.43 (3H, t, J 7.1 Hz, H6), 4.46 (2H, q, J 7.1 Hz, H5), 7.11 
(1H, s, H1), 7.50 (1H, d, J 8.8 Hz, H2), 7.81 (1H, dd, J 2.5, 8.9 Hz, H3), 8.31 (1H, 
d, J 2.5 Hz, H4); δC (100 MHz, CDCl3) 14.1, 63.1, 114.7, 119.5, 120.7, 125.7, 128.4, 137.7, 152.5, 154.8, 
160.2, 177.0; EI - m/z 295.9 [M]+; HPLC purity: 99 % (tr = 5.26 min).  
Ethyl 6-(4-(methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylate (SN83-3) 
Yellow solid (0.058 g, 49 %); M.p.: 158 – 162 oC; Rf (EtOAc) 0.53;  
δH (400 MHz, CDCl3) 1.34 (3H, t, J 7.1 Hz, H11), 3.03 (3H, s, H9), 4.34 (2H, q, 
 J 7.1 Hz, H10), 7.55 (1H, d, J 8.7 Hz, H2), 7.76 (2H, d, J 8.3 Hz, H5, H8), 7.87 (1H, 
dd, J 2.3, 8.7 Hz, H3), 7.98 (2H, d, J 8.3 Hz, H6, H7), 8.44 (1H, d, J 2.3 Hz, H4), 8.62 (1H, s, H1);  
δC (100 MHz, CDCl3) 14.2, 44.6, 61.5, 116.7, 119.2, 125.2, 128.1 (2C), 128.2 (2C), 132.9, 137.4, 140.2, 
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Ethyl 4-oxo-6-(4-(trifluoromethyl)phenyl)-4H-chromene-3-carboxylate (SN84-3)  
Brown solid (0.037 g, 83 %); M.p.: 109 – 111 oC; Rf (Hex/EtOAc 8:2) 0.65;  
δH (400 MHz, CDCl3) 1.42 (3H, t, J 7.1 Hz, H10), 4.41 (2H, q, J 7.1 Hz, H9), 7.61 
(1H, d, J 8.7 Hz, H2), 7.75 (4H, s, H5 – H8), 7.94 (1H, dd, J 2.4, 8.7 Hz, H3), 
8.51 (1H, d, J 2.3 Hz, H4), 8.69 (1H, s, H1); δC (100 MHz, CDCl3) 14.3, 61.5, 116.7, 119.0, 124.9 (2C), 
125.5, 126.0, 127.5 (2C), 129.9, 132.9, 137.9, 136.4, 145.1, 156.4, 161.7, 163.9, 179.6 EI - m/z 362.1 
[M]+; HPLC purity: 99 % (tr = 5.68 min).  
Ethyl 4-oxo-6-(6-(trifluoromethyl)pyridin-3-yl)-4H-chromene-3-carboxylate (SN85-3) 
Yellow solid (0.017 g, 24 %); M.p.: 141 – 143 oC; Rf (Hex/EtOAc 8:2) 0.57; 
δH (400 MHz, CDCl3) 1.43 (3H, t, J 7.1 Hz, H9), 4.42 (2H, q, J 7.1 Hz, H8), 7.67 
(1H, d, J 8.7 Hz, H2), 7.77 (1H, d, J 8.6 Hz, H7), 7.86 (1H, dd, J 2.4, 8.6 Hz, 
H6), 7.95 (1H, dd, J 2.4, 8.7 Hz, H3), 8.53 (1H, d, J 2.3 Hz, H4), 8.71 (1H, s, H1), 8.93 (1H, d, J 2.4 Hz, H5); 
δC (100 MHz, CDCl3) 14.3, 61.2, 116.8, 117.9, 119.6, 120.7, 122.0, 125.4, 126.3, 131.1, 132.8, 135.2, 
135.8, 148.4, 155.9, 161.8, 163.0, 177.6; EI - m/z 363.0 [M]+;  HPLC purity: 97 % (tr = 4.79 min).  
Ethyl 4-oxo-6-(thiophen-3-yl)-4H-chromene-3-carboxylate (SN87-3) 
Red solid (0.019 g, 85 %); M.p.: 54 – 56 oC; Rf (Hex/EtOAc 7:3) 0.68;  
δH (400 MHz, CDCl3) 1.39 (3H, t, J 7.1 Hz, H9), 4.39 (2H, q, J 7.1 Hz, H8), 7.43 
(2H, m, H2, H5), 7.50 (1H, d, J 8.7 Hz, H6), 7.55 (1H, d, J 2.3 Hz, H7), 7.91 (1H, 
dd, J 2.3, 8.7 Hz, H3), 8.45 (1H, d, J 2.3 Hz, H4), 8.64 (1H, s, H1); δC (100 MHz, CDCl3) 14.3, 61.4, 115.2, 
118.7, 120.7, 121.7, 123.5, 123.7, 124.1, 124.9, 126.2, 126.9, 132.3, 161.6, 165.8, 174.1; LRMS (EI) 
m/z 300.0 [M]+; HPLC purity: 98 % (tr = 5.33 min).  
Ethyl 6-(4-chlorophenyl)-4-oxo-4H-chromene-3-carboxylate (SN90-3) 
Brown solid (0.17 g, 78 %); M.p.: 128 – 131 oC; Rf (Hex/EtOAc 8:2) 0.48;  
δH (400 MHz, CDCl3) 1.40 (3H, t, J 7.1 Hz, H10), 4.40 (2H, q, J 7.1 Hz, H9), 7.43 – 
7.45 (4H, m, H5 – H8), 7.56 (1H, d, J 8.5 Hz, H2), 7.88 (1H, dd, J 2.3, 8.6 Hz, H3), 
8.44 (1H, d, J 2.3 Hz, H4), 8.67 (1H, s, H1); δC (100 MHz, CDCl3) 14.3, 61.5, 116.6, 118.8, 124.4, 125.5, 
128.5 (2C), 129.3 (2C), 132.7, 134.4, 137.5, 138.3, 155.2, 161.7, 163.3, 173.4; EI - m/z 328.0 [M]+; 
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Ethyl 4-oxo-6-(3-phenoxyphenyl)-4H-chromene-3-carboxylate (SN91-3) 
Brown crystalline solid (0.062 g, 48 %); M.p.: 31 – 34 oC; Rf (Hex/EtOAc 6:4) 
0.50; δH (400 MHz, CDCl3) 1.41 (3H, t, J 7.1 Hz, H6), 4.41 (2H, q, J 7.1 Hz, H5), 
7.08 (3H, m, Ar H), 7.32 – 7.39 (6H, m, Ar H), 7.55 (1H, d, J 8.7 Hz, H2), 7.89 
(1H, dd, J 2.3, 8.7 Hz, H3), 8.45 (1H, d, J 2.3 Hz, H4), 8.67 (1H, s, H1); δC (100 MHz, CDCl3) 14.3, 61.5, 
117.5, 118.3, 118.7, 119.1 (2C), 122.1, 122.9, 123.6, 124.5, 127.2, 127.6, 129.8 (2C), 130.4, 132.9, 
137.2, 138.8, 139.0, 158.1, 161.6, 163.3, 172.7; EI - m/z 385.9 [M]+; HPLC purity: 96 % (tr = 8.81 min).  
Ethyl 6-(2-methoxyphenyl)-4-oxo-4H-chromene-3-carboxylate (SN92-3) 
Brown solid (0.114 g, 69 %); M.p.: 42 – 45 oC; Rf (Hex/EtOAc 5:5) 0.55;  
δH (400 MHz, CDCl3) 1.41 (3H, t, J 7.1 Hz, H11), 3.81 (3H, s, H9), 4.41 (2H, q, 
 J 7.1 Hz, H10), 7.03 (2H, m, H6, H8), 7.35 (2H, m, H5, H7), 7.50 (1H, d, J 8.7 Hz, 
H2), 7.90 (1H, dd, J 2.2, 8.7 Hz, H3), 8.41 (1H, d, J 2.2 Hz, H4), 8.67 (1H, s, H1); δC (100 MHz, CDCl3) 
14.3, 55.6, 61.4, 111.4, 117.6, 117.8, 121.1, 124.9, 126.9, 127.1, 129.5, 130.9, 135.5, 135.8, 154.7, 
156.5, 161.6, 162.8, 173.5; EI - m/z 323.9 [M]+; HPLC purity: 99 % (tr = 5.28 min).  
Ethyl 5-(4-(methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylate (SN93-3) 
Brown solid (0.09 g, 83 %); M.p.: 157 – 160 oC; Rf (Hex/EtOAc 3:7) 0.25;  
δH (400 MHz, CDCl3) 1.29 (3H, t, J 7.1 Hz, H11), 3.09 (3H, s, H9), 4.28 (2H, q,  
J 7.1 Hz, H10), 7.15 (1H, d, J 7.4 Hz, H2), 7.41 (2H, d, J 8.6 Hz, H5, H6), 7.53 (1H, d,  
J 8.5 Hz, H4), 7.67 (1H, t, J 7.8 Hz, H3), 7.90 (2H, d, J 8.6 Hz, H7, H8), 8.57 (1H, s, 
H1); δC (100 MHz, CDCl3) 13.9, 44.4, 61.1, 116.9, 118.6, 122.1, 126.4 (2C), 128.9, 
129.2 (2C), 132.9, 138.8, 141.4, 146.6, 156.4, 160.2, 162.3, 172.9; EI - m/z 372.0 [M]+; HPLC purity:  
96 % (tr = 5.26 min).    
Ethyl 7-(4-(methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylate (SN94-3) 
Brown solid (0.09 g; 27 %); M.p.: 179 – 182 oC; Rf (Hex/EtOAc 4:6) 0.44;  
δH (400 MHz, CDCl3) 1.35 (3H, t, J 7.1 Hz, H11), 3.04 (3H, s, H9), 4.35 (2H, q,  
J 7.1 Hz, H10), 7.63 (2H, m, H2, H3), 7.77 (2H, d, J 8.1 Hz, H5, H6), 8.02 (2H, d, 
J 8.1 Hz, H7, H8), 8.32 (1H, d, J 8.3 Hz, H4), 8.63 (1H, s, H1); δC (100 MHz, 
CDCl3) 14.3, 44.7, 61.4, 117.2, 118.9, 122.4, 126.7 (2C), 129.3, 129.5 (2C), 133.2, 139.1, 141.9, 146.9, 
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Ethyl 8-(4-(methylsulfonyl)phenyl)-4-oxo-4H-chromene-3-carboxylate (SN95-3) 
Brown solid (0.01 g, 35 %); M.p.: 158 – 161 oC; Rf (Hex/EtOAc 2:8) 0.51;  
δH (400 MHz, CDCl3) 1.36 (3H, t, J 7.1 Hz, H11), 3.09 (3H, s, H9), 4.35 (2H, q,  
J 7.1 Hz, H10), 7.53 (1H, t, J 7.8 Hz, H3), 7.70 (3H, m, H2, H5, H6), 8.04 (2H, m, H7, 
H8), 8.33 (1H, d, J 7.9 Hz, H4), 8.59 (1H, s, H1); δC (100 MHz, CDCl3) 14.2, 44.5, 
61.5, 119.1, 123.7, 124.0, 125.8, 126.3, 127.3, 127.7 (2C), 130.5 (2C), 133.4, 
135.1, 140.9, 161.4, 170.6; EI - m/z 372.1 [M]+; HPLC purity: 95 % (tr = 7.51 min).    
5.3 Synthesis of 4-Aminoquinoline Derivative5 
N1-(7-Chloroquinolin-4-yl)ethane-1,2-diamine (SN08) 
4,7-Dichloroquinoline (2.0 g, 0.01 mol) and ethylene diamine (3.6 g, 0.06 mol, 
3.3 mL) were refluxed at 100 oC for 1 hour, and then at 140 oC for a further  
4 hours. The dark orange mixture was cooled to room temperature,  
1M NaOH (25 mL) was added, and extracted with ethyl acetate (3 x 50 mL). 
The organic layers were collected, washed with distilled water (2 x 50 mL) and dried over anhydrous 
MgSO4. The solvent was removed under reduced pressure to yield a pale-yellow solid (1.90 g, 85 %).  
M.p.: 128 - 131 oC; Rf (MeOH) 0.15; IR vmax (KBr) /cm
-1 1578 (C=N), 3254 (2 x N-H); δH (300 MHz, 
CD3OD) 2.98 (2H, t, J 6.3 Hz, H7), 3.44 (2H, t, J 6.4 Hz, H6), 6.56 (1H, d, J 5.7 Hz, H2), 7.40 (1H, dd,  
J 2.2, 9.0 Hz, H4), 7.78 (1H, d, J 2.2 Hz, H5), 8.11 (1H, d, J 9.0 Hz, H3), 8.36 (1H, d, J 5.6 Hz, H1);  
δC (75 MHz, CD3OD) 40.8, 46.1, 99.7, 118.8, 124.3, 126.1, 127.6, 136.7, 149.7, 152.4, 152.8;  
EI - m/z 221.6 [M]+; HPLC purity 99 % (tr = 12.5 min). 
5.4. Synthesis of Hybrid Derivatives 
5.4.1 General Synthetic procedure of Covalently-linked Hybrids (Series 1)6 
4-Aminoquinoline (1.0 eq) and aldehyde (1.0 eq) were dissolved in dry DCM (25 mL) and dry MeOH 
(2.5 mL) under N2 at room temperature. After 2 hours, NaBH(OAc)3 (3.0 eq) was added and the 
reaction mixture was stirred overnight. The reaction mixture was added to 2M NaOH (50 mL), and 
extracted with DCM:MeOH (4:1) (3 x 50 mL). The combined organic layers were dried over 
anhydrous Na2SO4, and concentrated. The residue was purified by flash chromatography on silica gel 




















Orange solid (0.26 g, 50 %); M.p.: 81 – 83 oC ; Rf (MeOH) 0.50;  
IR vmax (KBr) /cm
-1 1581 (C=N), 1653 (C=O), 3413 (strong, 2 x  
N-H); δH (400 MHz, DMSO-d6) 3.18 (2H, s, H6), 3.50 (2H, q,  
J 5.5 Hz, H7), 3.61 (2H, q, J 5.8 Hz, H8), 5.59 (1H, s, H1), 6.63 (1H, 
d, J 5.5 Hz, H9), 7.03 (1H, d, J 7.2 Hz, H2), 7.07 (1H, t, J 7.5 Hz, H4), 
7.44 (1H, m, NHa), 7.47 (1H, dd, J 2.0, 8.9 Hz, H12), 7.51 (1H, t, J 7.3 Hz, H3), 7.76 (1H, d, J 7.6 Hz, H5), 
7.81 (1H, d, J 2.2 Hz, H11), 8.29 (1H, d, J 9.1 Hz, H13), 8.42 (1H, d, J 5.4 Hz, H10), 10.21 (1H, m, NHb);  
δC (100 MHz, DMSO-d6) 44.1, 47.9, 52.5, 100.5, 116.8, 117.4, 118.2, 121.6, 123.8, 124.9, 125.2, 
127.8, 128.6, 133.5, 134.2, 149.7, 150.7, 152.2, 153.0, 155.7, 178.8; EI - m/z 379.0 [M]+; HPLC purity: 
97 % (tr = 6.36 min). 
6-Chloro-3-((2-(7-chloroquinolin-4-ylamino)ethylamino)methyl)-4H-chromen-4-one (SN24) 
Pink solid (0.37 g, 65 %); M.p.: 96 – 100 oC; Rf (MeOH) 0.48;  
IR vmax (KBr) /cm
-1 1576 (C=N), 1653 (C=O), 3375 (strong, 2 x  
N-H); δH (400 MHz, DMSO-d6) 3.20 (2H, s, H5), 3.47 (2H, q,  
J 5.7 Hz, H6), 3.58 (2H, q, J 5.8 Hz, H7), 5.58 (1H, s, H1), 6.57 (1H, 
d, J 5.5 Hz, H8), 7.02 (1H, d, J 8.6 Hz, H2), 7.40 (1H, m, NHa), 
7.43 (1H, dd, J 2.1, 8.9 Hz, H11), 7.46 (1H, dd, J 2.4, 8.6 Hz, H3), 7.64 (1H, d, J 2.6 Hz, H4), 7.79 (1H, d, 
 J 2.2 Hz, H10), 8.25 (1H, d, J 9.1 Hz, H12), 8.39 (1H, d, J 5.4 Hz, H9), 10.19 (1H, m, NHb); δC (100 MHz, 
DMSO-d6) 43.3, 47.0, 54.5, 99.0, 117.4, 120.2, 123.9, 124.6, 124.9, 125.4, 126.2,  127.9, 132.7, 133.4, 
149.9, 150.5, 151.8, 153.6, 154.1, 155.5, 176.3; EI - m/z 412.8 [M]+; HPLC purity: 98 % (tr = 7.96 min). 
6-Bromo-3-((2-(7-chloroquinolin-4-ylamino)ethylamino)methyl)-4H-chromen-4-one (SN25) 
Off-white solid (0.47 g, 75 %); M.p.: 122 – 125 oC; Rf (MeOH) 0.53; 
IR vmax (KBr) /cm
-1 1580 (C=N), 1656 (C=O), 3224 (strong, 2 x N-H); 
δH (400 MHz, DMSO-d6) 3.18 (2H, s, H5), 3.52 (2H, q, J 5.7 Hz, H6), 
3.62 (2H, q, J 5.9 Hz, H7), 5.62 (1H, s, H1), 6.61 (1H, d, J 5.5 Hz, H8), 
7.02 (1H, d, J 8.7 Hz, H2), 7.37 (1H, m, NHa), 7.48 (1H, dd, J 2.2, 8.9 Hz, H11), 7.59 (1H, dd,  
J 2.6, 8.6 Hz, H3), 7.79 (1H, d, J 2.2 Hz, H10), 7.81 (1H, d, J 2.6 Hz, H4), 8.27 (1H, d, J 9.1 Hz, H12), 8.42 
(1H, d, J 5.4 Hz, H9), 10.2 (1H, m, NHb); δC (100 MHz, DMSO-d6) 43.3, 47.0, 54.6, 102.2,  117.9, 120.7, 
122.0, 124.5, 124.7, 125.4, 127.9, 134.0, 136.1, 138.2, 149.4, 150.3, 152.2, 154.5, 155.5, 164.2, 


















Orange solid (0.25 g, 60 %); M.p.: 117 – 119 oC; Rf (MeOH) 0.56;  
IR vmax (KBr) /cm
-1 1576 (C=N), 1653 (C=O), 3215 (strong, 2 x N-H);  
δH (400 MHz, DMSO-d6) 3.20 (2H, s, H5), 3.47 (2H, q, J 5.5 Hz, H6), 
3.59 (2H, q, J 5.9 Hz, H7), 5.55 (1H, s, H1), 6.58 (1H, d, J 5.4 Hz, H8), 
7.03 (1H, d, J 8.8 Hz, H2), 7.23 (1H, dd, J 3.3, 8.5 Hz, H3), 7.38 (1H, d, 
J 3.3 Hz. H4), 7.40 (1H, m, NHa), 7.44 (1H, dd, J 2.2, 8.9 Hz, H11), 7.76 (1H, d, J 2.2 Hz, H10), 8.23 (1H, d, 
J 9.1 Hz, H12), 8.38 (1H, d, J 5.3 Hz, H9), 10.2 (1H, m, NHb); δC (100 MHz, DMSO-d6) 43.3, 46.9, 54.4, 
98.9, 110.5, 117.5, 119.4, 120.4, 124.1, 125.6,  127.5, 133.4, 149.2, 150.1, 151.3, 152.0, 154.1, 155.1, 
156.3, 158.3, 177.3 EI - m/z 395.1 [M]+; HPLC purity: 98 % (tr = 10.1 min). 
3-((2-(7-Chloroquinolin-4-ylamino)ethylamino)methyl)-6-methoxy-4H-chromen-4-one (SN27) 
Yellow solid (0.24 g, 41 %); M.p.: 94 – 98 oC; Rf (MeOH) 0.48;  
IR vmax (KBr) /cm
-1 1580 (C=N), 1658 (C=O), 3211 (strong, 2 x N-H); 
δH (400 MHz, DMSO-d6) 3.18 (2H, s, H5), 3.49 (2H, q, J 5.8 Hz, H6), 
3.56 (2H, q, J 5.8 Hz, H7), 3.94 (1H, s, OCH3), 5.47 (1H, s, H1), 6.62 
(1H, d, J 5.4 Hz, H8), 6.88 (1H, d, J 9.1 Hz, H2), 7.04 (1H, dd, J 3.2, 9.2 Hz, H3), 7.21 (1H, d, J 3.2 Hz. H4), 
7.43 (1H, m, NHa), 7.49 (1H, dd, J 2.1, 8.7 Hz, H11), 7.80 (1H, d, J 2.0 Hz, H10), 8.29 (1H, d, J 8.9 Hz, 
H12), 8.38 (1H, d, J 5.4 Hz, H9), 10.2 (1H, m, NHb); δC (100 MHz, DMSO- d6) 43.2, 46.6, 54.1, 55.2, 98.8, 
107.8, 117.3, 118.3, 119.9, 120.5, 121.5, 123.2, 123.7, 124.0, 127.3, 133.2, 148.8, 149.7, 151.7, 
153.7, 154.1, 177.7; EI - m/z 409.1 [M]+; HPLC purity: 98 % (tr = 7.36 min).  
3-((2-(7-Chloroquinolin-4-ylamino)ethylamino)methyl)-6-methyl-4H-chromen-4-one (SN28) 
Yellow solid (0.29 g, 52 %); M.p.: 118 – 120 oC; Rf (MeOH) 0.48;  
IR vmax (KBr) /cm
-1 1582 (C=N), 1651 (C=O), 3452 (strong, 2 x N-H); 
δH (400 MHz, DMSO-d6) 2.52 (3H, s, CH3), 3.15 (2H, s, H5), 3.47 
(2H, q, J 5.8 Hz, H6), 3.59 (2H, q, J 5.7 Hz, H7), 5.51 (1H, s, H1), 6.60 
(1H, d, J 5.4 Hz, H8), 6.89 (1H, d, J 8.2 Hz, H2), 7.20 (1H, dd, J 2.4, 8.4 Hz, H3), 7.24 (1H, m, NHa), 7.45 
(1H, dd, J 2.2, 8.9 Hz, H11), 7.53 (1H, d, J 2.4 Hz, H4), 7.78 (1H, d, J 2.2 Hz, H10), 8.26 (1H, d, J 9.0 Hz, 
H12), 8.39 (1H, d, J 5.4 Hz, H9), 10.1 (1H, m, NHb); δC (75 MHz, DMSO-d6) 20.2, 43.4, 46.7, 54.3, 101.6, 
117.4, 122.9, 124.1, 124.3, 125.1, 127.5, 130.4, 133.9, 134.2, 134.5, 147.0, 149.3, 150.3, 152.2, 
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5.4.2 General Synthetic Procedure of Amide-linked Hybrids at position 3 on the Chromone Ring 
(Series 2)7 
A solution of chromone-3-carboxylic acid (1.0 eq) and HOBt (1.3 eq) in DMF (3 mL) under N2 at 0 
oC 
was made, followed by the addition of a solution of EDC.HCl (1.3 eq) and a drop of Et3N in DMF  
(3 ml). Lastly, SN08 (1.5 eq) and DMAP (0.5 eq) in DMF (3 ml) were added in a dropwise fashion. The 
reaction mixture was stirred under N2 at 0 
oC for 30 minutes, then warmed to room temperature and 
stirred overnight. Distilled water (30 mL) was added to the reaction mixture and extracted with 
DCM:MeOH (4:1) (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4, and 
the solvent removed to afford the product. The residue was purified by flash chromatography on 
silica gel using DCM:MeOH (8:2) as the eluent to afford the product. 
 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-oxo-4H-chromene-3-carboxamide (SN44) 
Yellow solid (0.11 g, 49 %); M.p.: 118 – 120 oC; Rf (MeOH) 0.53; IR 
vmax (KBr) /cm
-1 1574 (C=N), 1632, 1731 (2 x C=O), 3423 (strong,  
2 x N-H); δH (400 MHz, DMSO-d6) 3.55 (2H, q, J 5.7 Hz, H6), 3.63 (2H, 
q, J 5.7 Hz, H7), 6.66 (1H, d, J 5.4 Hz, H8), 6.81 (1H, s, H1), 7.28 (1H, t, 
J 7.6 Hz, H4), 7.35 (1H, m, NHa), 7.45 (1H, d, J 7.9 Hz, H2), 7.70 (1H, d, J 8.9 Hz, H11), 7.80 (1H, s, H10), 
7.92 (1H, t, J 7.8 Hz, H3), 8.08 (1H, d, J 8.0 Hz, H5), 8.25 (1H, d, J 8.9 Hz, H12), 8.43 (1H, d, J 5.4 Hz, H9), 
10.1 (1H, s, NHb); δC (75 MHz, DMSO-d6) 36.8, 43.2, 99.8, 117.3, 118.1, 119.9, 123.7, 123.9, 127.4, 
127.9, 128.4, 133.3, 133.5, 148.9, 149.5, 151.7, 152.2, 156.1, 161.5, 162.1, 170.1; EI - m/z 393.0 [M]+; 
HPLC purity: 95 % (tr = 8.52 min). 
6-Chloro-N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-oxo-4H-chromene-3-carboxamide (SN48) 
Orange solid (0.19 g, 46 %); M.p.: 241 – 243 oC; Rf (MeOH) 0.52;  
IR vmax (KBr) /cm
-1 1582 (C=N), 1632, 1742 (2xC=O), 3418 (strong, 2 x 
N-H); δH (400 MHz, DMSO-d6) 3.52 (2H, q, J 5.4 Hz, H5), 3.57 (2H, q, 
 J 5.4 Hz, H6), 6.16 (1H, s, H1), 6.55 (1H, d, J 5.4 Hz, H7), 6.81 (1H, dd, 
J 2.5, 8.9 Hz, H10), 7.23 (1H, d, J 8.6 Hz, H2), 7.33 (1H, m, NHa), 7.60 
(1H, d, J 2.5 Hz, H9), 7.75 (1H, dd, J 2.2, 8.6 Hz, H3),  7.87 (1H, d, J 2.2 Hz, H4), 8.19 (1H, d, J 9.0 Hz, 
H11), 8.41 (1H, d, J 5.4 Hz, H8), 10.1 (1H, m, NHb); δC (75 MHz, DMSO-d6) 39.2, 44.2, 99.6, 113.8, 
117.1, 119.1, 121.3, 124.5, 125.3, 129.0, 129.8, 130.6, 134.9, 136.4, 149.8, 152.6, 154.6, 155.7, 



















Yellow solid (0.09 g, 36 %); M.p.: 98 – 101 oC; Rf (MeOH) 0.38;  
IR vmax (KBr) /cm
-1 1580 (C=N), 1625, 1703 (2 x C=O), 3241 (strong, 
2 x N-H); δH (400 MHz, DMSO-d6) 3.42 (2H, q, J 5.7 Hz, H5), 3.64 
(2H, q, J 5.8 Hz, H6), 6.17 (1H, s, H1), 6.64 (1H, d, J 5.6 Hz, H7), 6.82 
(1H, d, J 8.8 Hz, H2), 7.33 (1H, dd, J 2.3, 9.0 Hz, H10), 7.40 (1H, dd, J 2.4, 8.8 Hz, H3), 7.45 (1H, m, NHa), 
7.79 (1H, d, J 2.2 Hz, H9), 7.98 (1H, d, J 2.4 Hz, H4), 8.25 (1H, d, J 9.1 Hz, H11), 8.46 (1H, d, J 5.5 Hz, H8), 
10.1 (1H, m, NHb); δC (100 MHz, DMSO-d6) 38.8, 42.3, 99.7, 117.3, 119.3, 121.6, 123.8, 124.2, 125.8, 
129.9, 130.4, 133.5, 135.7, 136.4, 148.4, 150.1, 151.3, 153.1, 156.8, 161.2, 175.4; EI - m/z 472.1 [M]+; 
HPLC purity: 94 % (tr = 8.03 min). 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-6-fluoro-4-oxo-4H-chromene-3-carboxamide (SN55) 
Orange solid (0.25 g, 62 %); M.p.: 118 – 121 oC; Rf (MeOH) 0.42; IR 
vmax (KBr) /cm
-1 1550 (C=N), 1696, 1733 (2 x C=O), 3240 (strong, 2  
x N-H); δH (400 MHz, DMSO-d6) 3.91 (4H, m, H5, H6), 6.56 (1H, d,  
J 5.5 Hz, H7), 6.89 (1H, s, H1), 7.38 (2H, m, H2, H10), 7.72 – 7.78 (4H, 
m, H3, H4, H9, NHa), 8.28 (1H, d, J 9.0 Hz, H11), 8.48 (1H, d, J 5.6 Hz, H8), 9.70 (1H, s, NHb); δC (100 MHz, 
DMSO-d6) 39.2, 44.3, 99.5, 113.6, 117.9, 121.1, 121.3, 122.2, 124.8, 125.6, 129.1, 130.2, 134.9, 
149.3, 152.5, 152.9, 154.5, 159.8, 161.1, 162.5, 176.5; EI - m/z 410.8 [M]+; HPLC purity: 95 %  
(tr = 8.65 min). 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-6-methoxy-4-oxo-4H-chromene-3-carboxamide (SN56) 
Yellow solid (0.13 g, 46 %); M.p.: 81 – 85 oC; Rf (MeOH) 0.55; IR vmax 
(KBr) /cm-1 1533 (C=N), 1687, 1740 (2 x C=O), 3238 (strong, 2  
x N-H); δH (400 MHz, DMSO-d6) 3.42 (2H, q, J 5.7 Hz, H5), 3.51 (2H, 
q, J 5.8 Hz, H6), 3.85 (3H, s, OCH3), 6.61 (1H, d, J 5.4 Hz, H7), 6.81 
(1H, s, H1), 7.35 – 7.42 (4H, m, H2, H3, H9, NHa); 7.74 (1H, d, J 9.0 Hz, 
H10), 7.83 (1H, d, J 3.1 Hz, H4), 8.28 (1H, d, J 9.0 Hz, H11), 8.46 (1H, d, J 5.5 Hz, H8), 10.1 (1H, s, NHb);  
δC (100 MHz, DMSO-d6) 37.3, 42.4, 55.7, 98.9, 111.4, 117.3, 118.1, 120.7, 120.8, 123.7, 123.9, 124.8, 
125.4, 127.4, 133.3, 149.8, 151.7, 152.1, 156.2, 162.7, 163.9, 177.6; EI - m/z 422.8 [M]+; HPLC purity: 




















Orange solid (0.16 g, 52 %); M.p.: 82 – 86 oC; Rf (MeOH) 0.50; IR 
vmax (KBr) /cm
-1 1565 (C=N), 1655, 1748 (2 x C=O), 3435 (strong, 2  
x N-H); δH (400 MHz, DMSO-d6) 2.28 (3H, s, CH3), 3.49 (2H, q, J 5.8 
Hz, H5), 3.58 (2H, q, J 5.8 Hz, H6), 6.07 (1H, s, H1), 6.60 (1H, d, J 5.3 
Hz, H7), 6.69 (1H, d, J 8.1 Hz, H2), 7.14 (1H, dd, J 2.1, 8.3 Hz, H3), 7.45 (2H, m, H4, NHa), 7.77 (1H, dd,  
J 2.4, 9.1 Hz, H10), 7.87 (1H, d, J 2.5 Hz, H9), 8.23 (1H, d, J 9.2 Hz, H11), 8.41 (1H, d, J 5.3 Hz, H8), 10.0 
(1H, s, NHb); (100 MHz, DMSO-d6) 20.1, 41.5, 43.3, 98.7, 117.2, 119.5, 123.9, 124.0, 126.8, 127.9, 
128.3, 133.4, 134.6, 135.0, 149.0, 149.9, 151.9, 152.3, 156.1, 159.5, 162.7, 175.1; EI - m/z 407.1 [M]+; 
HPLC purity: 97 % (tr = 8.86 min).  
5.4.3 General Synthetic Procedure of Amide-linked Hybrids at position 2 on the Chromone Ring 
(Series 3)7 
A similar procedure was used as for the synthesis of Series 2 (Section 5.4.2), except that the 
chromone-2-carboxylic acids were used.  
 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-oxo-4H-chromene-2-carboxamide (SN74) 
Yellow solid (0.25 g, 46 %); M.p.: 241 – 243 oC; Rf (MeOH) 0.52; IR 
vmax (KBr) /cm
-1 1580 (C=N), 1650, 1741 (2 x C=O), 3435 (strong, 2 x 
N-H); δH (400 MHz, DMSO-d6) 3.67 (2H, q, J 5.9 Hz, H6), 3.74 (2H, q, J 
6.0 Hz, H7), 6.81 (1H, d, J 5.5 Hz, H8), 6.99 (1H, s, H1), 7.59 (1H, dd,  
J 2.2, 8.9 Hz, H11), 7.68 (2H, m,  H4, NHa), 7.85 (1H, d, J 8.5 Hz, H2), 
7.93 (1H, d, J 2.2 Hz, H10), 8.03 (1H, t, J 8.7 Hz, H3), 8.19 (1H, d, J 7.9 Hz, H5), 8.36 (1H, d, J 9.0 Hz, H12), 
8.57 (1H, d, J 5.4 Hz, H9), 9.49 (1H, m, NHb); δC (100 MHz, DMSO-d6) 38.4, 41.9, 99.2, 111.1, 118.1, 
119.2, 124.2, 124.6, 124.7, 125.5, 126.6, 128.0, 134.0, 135.6, 149.6, 150.6, 152.4, 155.6, 156.1, 
160.1, 177.8; EI - m/z 393.1 [M]+; HPLC purity: 95 % (tr = 8.62 min).  
6-Chloro-N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-oxo-4H-chromene-2-carboxamide (SN75) 
Pale-brown solid (0.41 g, 70 %); M.p.: 173 – 175 oC; Rf (MeOH) 0.56; 
IR vmax (KBr) /cm
-1 1578 (C=N), 1686, 1731 (2 x C=O), 3323 (strong, 2  
x N-H); δH (400 MHz, DMSO-d6) 3.37 (2H, q, J 5.6 Hz, H5), 3.49 (2H, q,  
J 5.7 Hz, H6), 6.75 (1H, d, J 5.6 Hz, H7), 6.87 (1H, s, H1), 7.40 (1H, dd,  
J 2.3, 8.6 Hz, H10), 7.51 (1H, d, J 8.0 Hz, H2), 7.64 (1H, d, J 2.2 Hz, H9), 
7.69 (1H, dd, J 2.1, 7.9 Hz, H3), 7.94 (1H, m, NHa), 7.98 (1H, d, J 2.0 Hz, H4), 8.40 (1H, d, J 8.8 Hz, H11), 
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122.5, 123.6, 123.8, 125.3, 126.4, 128.7, 130.2, 134.5, 135.5, 139.4, 146.9, 152.9, 155.4, 158.9, 
169.7, 175.8; EI - m/z 427.0 [M]+; HPLC purity: 96 % (tr = 9.23 min).  
6-Bromo-N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-oxo-4H-chromene-2-carboxamide (SN76) 
Off-white solid (0.42 g, 72 %); M.p.: 143 – 145 oC; Rf (MeOH) 0.42;  
IR vmax (KBr) /cm
-1 1544 (C=N), 1688, 1739 (2 x C=O), 3237 (strong,  
2 x N-H); δH (300 MHz, DMSO-d6) 3.39 (2H, q, J 6.0 Hz, H5), 3.58 (2H, 
q, J 6.1 Hz, H6), 6.87 (1H, s, H1), 7.16 (1H, d, J 5.6 Hz, H7), 7.38 (1H, d, 
J 8.9 Hz, H2), 7.69 (1H, dd, J 2.4, 8.9 Hz, H10), 7.94 (1H, dd,  
J 2.4, 8.9 Hz, H3), 7.99 (1H, m, NHa), 8.06 (1H, d, J 2.5 Hz, H4), 8.11 (1H, d, J 2.4 Hz, H9), 8.45 (1H, d,  
J 8.9 Hz, H11), 8.56 (1H, d, J 5.6 Hz, H8), 9.52 (1H, s, NHb); δC (100 MHz, DMSO-d6) 39.5, 44.2, 99.2, 
114.4, 117.5, 118.8, 121.6, 123.2, 124.8, 126.1, 129.4, 134.1, 134.9, 141.1, 149.3, 152.7, 154.5, 
156.2, 163.8, 166.5, 178.5; EI - m/z 472.8 [M]+; HPLC purity: 95 % (tr = 8.04 min).    
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-6-fluoro-4-oxo-4H-chromene-2-carboxamide (SN77) 
Brown solid (0.38 g, 65 %); M.p.: 240 – 242 oC; Rf (MeOH) 0.45;  
IR vmax (KBr) /cm
-1 1552 (C=N), 1690, 1735 (2 x C=O), 3241 (strong,  
2 x N-H); δH (300 MHz, DMSO-d6) 3.50 (4H, m, H5, H6), 6.66 (1H, d,  
J 5.4 Hz, H7), 6.87 (1H, s, H1), 7.46 (2H, m, H2, H10), 7.75 – 7.79 (4H, 
m, H3, H4, H9, NHa), 8.23 (1H, d, J 8.9 Hz, H11), 8.44 (1H, d, J 5.4 Hz, 
H8), 9.31 (1H, m, NHb); δC (100 MHz, DMSO-d6) 38.5, 42.0, 99.2, 110.2, 117.9, 119.2, 121.9, 123.3, 
124.3, 124.6, 127.7, 133.9, 146.4, 149.2, 150.7, 151.9, 156.3, 158.5, 159.9, 160.9, 176.9; LRMS (EI) 
m/z 410.9 [M]+; HPLC purity: 96 % (tr = 9.36 min).   
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-6-methoxy-4-oxo-4H-chromene-2-carboxamide (SN78) 
Brown solid (0.41 g, 55 %); M.p.: 113 – 115 oC; Rf (MeOH) 0.58; IR 
vmax (KBr) /cm
-1 1535 (C=N), 1686, 1735 (2 x C=O), 3241 (strong,  
2 x N-H); δH (300 MHz, DMSO-d6) 3.56 (2H, q, J 5.7 Hz, H5), 3.62 (2H, 
q, J 5.7 Hz, H6), 3.87 (3H, s, OCH3), 6.67 (1H, d, J 5.2 Hz, H7), 6.83 
(1H, s, H1), 7.41 (1H, d, J 8.9 Hz, H2), 7.45 (1H, dd, J 2.2, 9.0 Hz, H10), 
7.56 (1H, dd, J 2.7, 8.9 Hz, H3), 7.65 (1H, m, NHa), 7.80 (1H, d, J 2.8 Hz, H4), 8.41 (1H, d, J 2.2 Hz, H9), 
8.23 (1H, d, J 9.0 Hz, H11), 8.44 (1H, d, J 5.2 Hz, H8), 9.28 (1H, m, NHb); δC (100 MHz, DMSO-d6) 37.7, 
41.4, 55.6, 98.4, 114.6, 117.1, 119.9, 123.0, 123.6, 123.8, 125.4, 126.9, 128.5, 133.2, 146.1, 148.4, 
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5.5 Biological Testing Protocols 
Antiplasmodial Testing Protocol 
The samples were tested in triplicate against chloroquine-sensitive (D10 and NF54) and  
-resistant (K1) strains of P. falciparum. Continuous in vitro cultures of asexual erythrocyte stages of 
P. falciparum were maintained using a modified method of Trager et al.8 Quantitative assessment of 
antiplasmodial activity in vitro was determined via the parasite lactate dehydrogenase assay using a 
modified method described by Makler et al.9 The test samples were prepared as a  
20 mg/mL stock solution in 100 % DMSO and sonicated to enhance solubility. Samples were tested 
as a suspension if not completely dissolved. Stock solutions were stored at -20 oC. Further dilutions 
were prepared on the day of the experiment. Chloroquine was used as the reference drug in all 
experiments. A full dose-response was performed for all compounds to determine the concentration 
inhibiting 50 % of parasite growth (IC50 value). Test samples were tested at a starting concentration 
of 1000 ng/mL, which was then serially diluted 2-fold in complete medium to give 10 concentrations; 
with the lowest concentration being 2 ng/mL. The same dilution technique was used for all samples. 
The highest concentration of solvent to which the parasites were exposed to had no measurable 
effect on the parasite viability. The IC50 values were obtained using a non-linear dose-response curve 
fitting analysis via Graph Pad Prism v.4.0 software. 
Antitumour Testing Protocol 
The MTT assay was used to calculate IC50 values in WHCO1 cancer cells. The IC50 values were 
determined using a range of concentrations (0, 0.1, 1, 5, 10, 50, 100 and 200 µM). Cells were plated 
at 3000 cells per well, in triplicate, in 90 µL of media in 96-well plates and incubated overnight at  
37 °C in a humidified atmosphere of 5 % CO2. Media alone (90 µL) was also plated in triplicate and 
incubated at 37 oC under 5 % CO2. The cells (and media alone) were treated with 10 µL drug diluted 
in media and DMSO, to give a final DMSO concentration of 0.2 %. The cells were incubated for  
48 hours after which 10 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
solution was added to each well and incubated for 4 hours. MTT reagent consists of yellow 
tetrazolium salt that is reduced to purple formazan crystals in the mitochondria of living cells. After 
the 4 hour incubation period, the formazan crystals were solubilized by the addition of 100 µL 
solubilization solution (10 % w/v SDS, 0.01 M HCl) overnight at 37 oC, 5 % CO2. The absorbance, 
which represents cell viability, was subsequently measured at 595 nm, and corrected. The IC50 values 
were calculated using GraphPad Prism version 4.03. The dose-response curves were generated by 
non-linear regression analysis (Non-linear regression (Sigmoidal dose-response with variable slope)) 
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Antimycobacterial Testing Protocol 
The MIC was determined using a standard broth microdilution method.10, 11 A 10 mL culture of 
Mycobacterium tuberculosis, H37Rv was grown to an OD600 of 0.6 – 0.7. The culture was then diluted 
1:500 in liquid 7H9 medium, 50 μL of 7H9 medium was added.12 The compounds were added in 
duplicate, at a final concentration of 640 µM (stocks were made up to a concentration of 12.8 mM in 
DMSO, and diluted to 640 µM in 7H9 medium). A 2-fold serial dilution was prepared. Controls 
include media only, 5 % DMSO, Rifampicin and Kanamycin. Finally, 50 μL of the 1:500 diluted  
M. tuberculosis culture was added. The microtitre plate was sealed in a ziplock bag and incubated at 
37 °C with humidifier to prevent evaporation of liquid. The lowest concentration of drug that inhibits 
growth of more than 90 or 99 % of the bacterial population is considered to be the MIC90 or MIC99. 
MIC99 values are scored visually at 7 days and 14 days post inoculation, and digital images captured 
and stored.  
Turbidimetric Solubility Assay Protocol 
Preparation of 0.01M pH 7.4 Phosphate Buffered Saline (PBS) involved dissolving 1 intact PBS buffer 
tablet (EC Diagnostics AB, Sweden) in sufficient distilled wat r to make 1000 mL of a solution 
comprising 0.14M NaCl, 0.003M KCl and 0.01M phosphate buffer. This solution was filtered through 
a 0.22 µm nylon filter to remove any particulate contaminants and the pH ascertained using a pH 
meter. The test compounds were prepared by making a 10mM stock solutions by accurately 
weighing and dissolving each in sufficient DMSO to approximately 1000 µL final volume. From each 
pre-dilution solution, secondary dilutions of the compounds in both DMSO and 0.01M pH 7.4 PBS 
were prepared in a 96-well plate, in triplicate. Wells in columns 1–6 contained compound in DMSO 
while those in columns 7–12 contained samples in PBS at similar nominal concentrations as those in 
DMSO. The final volume of solvent in each assay plate well was 200 µL, prepared by pipetting 4 µL 
each of solution from the pre-dilution plate to the corresponding well into both DMSO and PBS (both 
196 µL). This ensured that the final concentration of DMSO in the PBS aqueous buffer did not exceed 
2 % v/v. The different concentrations in DMSO were prepared to serve as controls to determine 
potential false turbimetric absorbance readings arising from the compounds in solution absorbing 
incident radiation at the analysis wavelength. After making the assay plate preparation, the plate 
was covered and left to equilibrate for 2 hours at ambient room temperature. After incubation, UV-
Vis absorbance readings from the plate were measured at 620 nm. Corrected absorbance readings at 
different concentrations of test compounds were calculated by subtracting absorbance of the blank 
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